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ABSTRACT OF DISSERTATION

NEUROCHEMICAL STUDIES OF ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER MEDICATIONS IN THE STRIATUM AND
NUCLEUS ACCUMBENS OF THE FISCHER 344 RAT
Stimulant medications such as D-amphetamine, mixed-salts (75% D- and
25% L-) amphetamine; Adderall®, and methylphenidate are first-line treatments
for Attention-Deficit/Hyperactivity Disorder (ADHD). In vivo studies have
predominantly focused on these stimulants in the context of drug abuse, and
their therapeutic mechanistic properties are only theoretical. Previously, in vivo
techniques have been limited by poor temporal and spatial resolution, and
characterizations of these medications in rodent models have not been possible
at low, clinically relevant levels. In order to address these issues, our laboratory
used in vivo high speed chronoamperometric microelectrodes to characterize the
effects of local applications of D-amphetamine, L-amphetamine, D,Lamphetamine, and Adderall® at low levels in the striatum and nucleus
accumbens of 3-6 month old, male Fischer 344 (F344) rats. Our results showed
significant differences between the faster kinetics of dopamine (DA) release
signals caused by D,L-amphetamine and the slower kinetics resulting from Damphetamine. These data support that resulting DA concentrations evoked by Dand D,L-amphetamine are correlated with the amount of D-amphetamine in the
drug and only the time courses of the signals are affected by L-amphetamine.
Additionally, locally applied D- and L-amphetamine caused DA release signals
with similar amplitudes or concentrations of evoked DA; however, the signals
were significantly faster for L-amphetamine. Adderall® caused significantly
greater DA release that lasted over a longer time course compared to DA release
caused by D- or D,L-amphetamine. These data support the hypothesis that
amphetamine isomers, alone or in combination, interact differently with the DA
transporter (DAT) to subsequently cause reversal of transport of DA out of
presynaptic membranes of DA neuronal projections. Finally, reverse
microdialysis studies were carried out to assess low levels of D-amphetamine,
Adderall® (75% D-, 25% L-amphetamine), methylphenidate, and a new mixedsalts amphetamine that we referred to as Reverse Adderall (75% L-, 25% D-

amphetamine) in the striatum of F344 rats. These data reveal a stimulant
concentration-response curve for DA with double plateaus that may be explained
by dual mechanisms of reverse transport of DA through the DAT. In addition,
reverse microdialysis of methylphenidate caused DA overflow similar to the
effects of the other stimulants.
KEYWORDS: ADHD, Amphetamine, Dopamine, Voltammetry, Microdialysis
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Chapter 1: Introduction
Attention-Deficit/Hyperactivity Disorder
This

dissertation

neurochemical

describes

properties

of

work

completed

medications

Deficit/Hyperactivity Disorder (ADHD).

to

prescribed

investigate
for

the

Attention-

Concerns are often raised about the

validity of such a disorder, due in part to the increasing use of stimulant
medications in children over the last decade. However, a growing body of data
exists regarding the neurobiological basis of ADHD symptoms with increasing
evidence that the disorder is continual from childhood to adulthood. ADHD is not
a unique disorder to the United States and has a cross-cultural prevalence in the
estimated range of 3-17% with an estimated prevalence of 5-10% in elementary
school age children (Lahey et al. 1999). Likewise, adult ADHD prevalence is
accurately estimated to be 2-4% due to improved recognition and diagnosis in
adults (Kessler et al. 2005).
Although stimulants used to treat ADHD are very safe medications with a
long track record of clinical use, they are under increasing scrutiny due to some
isolated rare cardiac deaths while using the medications. The news media have
been buzzing about a proposed “black-box” warning for stimulant medications,
which would alert physicians and patients that a drug carries rare but significant
risks (Vendantam 2006). Proposals are under review to require the warning by
the Food and Drug Administration on medications such as Ritalin®, Adderall®,
and Dexedrine®, all discussed in the text of this dissertation. Fewer than 10% of
prescription drugs carry such a warning (Vedantam 2006). As of 2004, sales of
all ADHD drugs totaled $3.1 billion, and an estimated 2.5 million children and 1.5
million adults were using these medications (Vedantam 2006; Mathews 2006).
George Still first described the condition clinically termed now as ADHD in
1901 by noticing the symptoms of “over-activity, inattention, poor inhibitory
volition, aggressiveness, defiance, resistance to discipline, lawlessness,
spitefulness, and dishonesty” that were observed in over 20 children (Still 1902).
In an early Diagnostic and Statistical Manual of Mental Disorders (1968) the
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condition was given the name of Hyperkinetic Disorder of Childhood. Today, the
current DSM-IV-TR (2000) classifies the disorder as ADHD with three distinct
subtypes: 1) predominantly inattentive 2) predominantly hyperactive-impulsive
and 3) combined. Each subtype requires the fulfillment of at least six of nine
symptoms present prior to age seven. Symptoms must persist in two or more
settings, and clearly demonstrate clinically significant impairment in social,
academic, or occupation functioning (DSM-IV-TR, 2000).
ADHD Etiology
Many studies have investigated the etiology of ADHD including genetic,
neuroimaging, and electrophysiological pursuits. Familial studies have found a
greater risk for siblings and parents of children with ADHD (Faraone and
Biederman 1994). The risk for the disorder was found to be higher in biological
than adopted children of ADHD individuals (Morrison and Stewart 1973). Twin
studies have been carried out to investigate heritability, shared environment, and
non-shared environments.

Conclusive evidence supported that deficient

parenting and family adversity did not lead to the manifestation of ADHD (Levy et
al. 1997; Goodman and Stevenson 1989).

Finally, studies that investigated

correlations with lower socioeconomic status, higher psychosocial adversity, and
increased parental conflict found no direct links (Scahill et al. 1999; Biederman et
al. 1995a, 1995b). Conclusive evidence points to common genetic vulnerability
of probands and first-degree relatives.
To date, components of the dopaminergic system have been studied
because of the consensus that dysregulation of dopaminergic neurotransmission
is central to the disorder.

The dopamine transporter (DAT) and the allelic

variation in the DAT gene, DAT1, have been associated with ADHD and remain
functionally unexplained (Cook et al. 1995). The dopamine (DA) D4 receptor
(D4R), having seven 48 base pair repeats in exon 3, is slightly less effective than
other variants in the inhibition of the second messenger cAMP. Activated cAMP
has been shown to impair function in the prefrontal cortex. (Asghari et al. 1995).
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DAT1 and D4R genes are modestly accepted to be associated with susceptibility
to ADHD.
Neuroimaging studies have investigated the anatomical substrates of
ADHD and support dysfunction and dysregulation in multiple brain regions. Data
support anomalies in cerebellar-striatal/adrenergic-prefrontal circuitry which can
be improved by use of stimulant medications (Castellanos et al. 1996; Solanto et
al. 2001). It is widely accepted that dysfunction within this distributed circuit
underlies the symptomatology of ADHD.

These circuits specifically include

multiple brain regions such as right prefrontal cortex, the caudate nucleus, globus
pallidus, and cerebellar vermis, all reported to have reduced volumes in ADHD
individuals consistent with the possibility of hypofunctionality of normal brain
function (Castellanos et al. 1996).

However, these findings are given with

caution due to normal variability in anatomical brain measures and the inclusion
of treated and untreated individuals (Solanto et al. 2001).
Dopamine Function in the Normal Mammalian Central Nervous System
An extensive review of DA neurotransmission, including interactions with
other neurotransmitters, is beyond the scope of this thesis; however, the
following outline provides a general explanation of the system we investigated.
In the next section, the effects of stimulants will be described in the context of DA
neurotransmission. DA synthesis is initiated in the soma of DA neurons by the
precursor, L-tyrosine, being converted to 3,4-dihydroxyphenylalanine (DOPA) via
the enzyme tyrosine hydroxylase (TH) (Cooper et al. 1996; Seiden and Dykstra
1977).

The decarboxylation of DOPA into DA by L-aromatic amino acid

decarboxylase is the final synthetic step in neurons that use DA as their primary
neurotransmitter (Fig. 1.1). TH activity is determined via end-product inhibition
and phosphorylation (Cooper et al. 1996). During times of increased need for DA
neuronal release, new TH protein can be synthesized or TH activity will be
increased to meet the demands of the releasing neuron. TH is described to be
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the rate limiting step in the synthesis of DA based on known saturation levels of
TH (Squire et al. 2003)(Fig 1.1).
The majority of cell bodies that synthesize DA in the brain lie in the zona
compacta of the substantia nigra (SN) and project via the nigrostriatal pathway to
the striatum, including the caudate nucleus, putamen, and the amygdala (Solanto
et al. 2001; Cooper et al. 1996). The mesolimbic pathway originates from DA
synthesis in the cell bodies located in the ventral medial tegmentum. These DA
projections run lateral to the nigrostriatal pathway and innervate the nucleus
accumbens, olfactory tubercle, and selective regions of the prefrontal cortex
forming the mesocortical pathway. Projections exist as well from the midbrain to
the

anterior

cingulated

cortex

(mesocortical

pathway),

and

finally

the

tuberoinfundibular tract that forms from the arcuate nucleus projecting to the
pituitary gland (Dahlstrom and Fuxe 1964; Lindvall and Bjorklund 1974; Seiden et
al. 1993). DA levels are highest in the striatum (10 µg/g), nucleus accumbens (5
µg/g), olfactory tubercle (6 µg/g), but much less in the cortex (0.1 µg/g) (Cooper
et al. 1996).
Following synthesis, DA is released through two mechanisms: impulse
dependent release and transporter-mediated release.

Cytoplasmic DA is

packaged into the vesicles via the Mg2+-dependent vesicular monoamine
transporter, VMAT2, predominantly found in brain catecholamine neurons
(Solanto et al. 2001; Cooper et al. 1996).

Vesicles concentrate near the

presynaptic terminal where they remain primed for cellular membrane fusion and
subsequent exocytosis thereby releasing the stored DA into the synaptic cleft.
DA release from vesicles predominantly occurs via a Ca2+-dependent exocytotic
process whereby Ca2+ influx leads to ATP hydrolysis and depolarization of the
membrane (Winkler 1988; Seiden and Sabol 1993).

Transporter-mediated

release of DA occurs mainly as a result of pharmacologic manipulation of the
DAT in the presence of uptake inhibitors such as amphetamine (Blaszkowski and
Bogdanski 1972; Paton 1973) (Fig 1.2).
Following release of DA, multiple synaptic targets determine the
downstream effects on future DA release.
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For example, DA stimulates

presynaptic DA receptors (autoreceptors) that exist on most parts of the DA
neuron and are a part of the D2 receptor family (Civelli et al. 1993; Cooper et al.
1996; Squire et al. 2003). The D2 family contains D2, D3, and D4 subtypes of
receptors, with DA receptor 2 (D2R) primarily found as an autoreceptor that
regulates future DA synthesis and release. Release-modulating autoreceptors
function to provide feedback inhibition of further transmitter release and can be
found on neurons that release other neurotransmitters. Synthesis-modulating
autoreceptors are suggested to regulate DA synthesis based on increases in DA
synthesis in the presence of DA receptor antagonists (Squire et al. 2003). The
D2Rs are localized to the striatum, nucleus accumbens, olfactory tubercle, and
neuron cell bodies in the substantia nigra and ventral tegmental area. They most
often serve as autorceptors that inhibit future DA synthesis and release.

D3

receptors are mainly found in the nucleus accumbens, olfactory tubercle, and
hypothalamus. They are sparsely found in the caudate, cortex and DA neurons
originating in the substantia nigra. These receptors, primarily autoreceptors, are
less abundant than D2Rs and are thought to inhibit Ca2+ entry into the
presynaptic cell. D4Rs are predominantly located in the frontal cortex, midbrain,
and amygdala, are less in number than D2Rs, and are proposed to be highly
variable in humans. Impulse-modulating autoreceptors located to the soma and
dendrites of DA neurons regulate overall cellular firing rate (Cooper et al. 1996).
The D1 type DA receptor family classifies two DA receptor subtypes, D1
and D5.

The D1 receptors are most highly concentrated in the striatum and

nucleus accumbens and typically lead to the stimulation of adenylate cyclase and
increase IP3 turnover. D5 receptors are most often found in the hippocampus and
hypothalamus, but can be found in the striatum and nucleus accumbens and
have been shown to stimulate adenylate cyclase (Cooper et al. 1996).
The termination of DA neurotransmission is accomplished via three
distinct mechanisms. The first is diffusion away from a receptor followed by
dilution in extracellular (EC) fluid to subphysiological levels. Second, enzymes
can inactivate EC and intracellular (IC) DA such as monoamine oxidase (MAO)
and catechol-O-methyl-transferase (COMT).
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Finally, the NaCl-dependent

neuronal DAT, having 12 transmembrane domains, can accumulate both IC DA
and NE. DAT function is Na+- and temperature-dependent and requires 2 Na+
ions and 1 Cl- ion for activation (Harris and Baldessarini 1973; Holz and Coyle
1974; Krueger 1990).
Stimulant Treatments of ADHD
Amphetamine Isomers
In 1887, synthetic amphetamine was invented by Lazar Edeleano, a
student at the University of Berlin studying under A. W. Hofmann (Edeleano
1887).

It received this generic name from a contraction of α-methyl-

phenethylamine and today boasts greater than 20 trade names as described by
the Merck Index listing (Sulzer et al. 2005). Amphetamine became available
commercially in 1932 as Benzedrine® (50% D-, 50% L- amphetamine), available
primarily in inhaler form for treatment of narcolepsy. Over time, Benzedrine® was
made available in tablet form as an over-the-counter medication (Prinzmetal and
Bloomberg 1935). Within the first three years of availability, greater than 50
million Benzedrine® tablets were sold (Sulzer et al. 2005). In the 1970s, 10
billion tablets were produced annually leading to the imposition of legal quotas
brought forth by the United States Justice Department (Sulzer et al. 2005).
Amphetamine has been administered in all major United States wars and military
conflicts to promote alertness among the troops, in particular the air forces for
flights and bombing missions lasting many hours (Caldwell et al. 2003). While
amphetamine derivatives have more than 30 known uses, its use as a treatment
for ADHD surpasses them all. The National Institute of Mental Health (NIMH)
estimates an occurrence of ADHD in 3-5% of the population; and two million
prescriptions are written per month for stimulant medications to treat ADHD
(Vendantam 2006).
In general, it is believed that amphetamine interacts with the uptake
process of released catecholamines. Amphetamine is thought to mimic DA and
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is taken up into the synaptic terminal via the DAT in a competitive relationship
with DA. Amphetamine then interferes with the normal uptake process of DA and
causes a reversal of normal DAT function (Kuczenski 1983; Reith et al. 1986;
Heikkila et al. 1975). Catecholamine release is thought to be independent of
spike activity supported by amphetamine-induced release of DA that was
inhibited by drugs that interfere with catecholamine synthesis such as α-methylpara-tyrosine (Solanto et al. 2001).

Likewise, the majority of released

catecholamines in the presence of amphetamine undergo reverse transport
through the DAT rather than release after Ca2+-dependent spike activity (Cooper
et al. 1996). Amphetamine will also accumulate catecholamines released due to
spike activity as the drug is thought to block normal reuptake of DAT or the
norepinephrine transporter (NET) (Solanto et al. 2001) (Fig 1.2).
The following effects of amphetamine have been described at the
monoaminergic synapse:

a) inhibition of monoamine oxidase (MAO), b)

blockade of reuptake by the DAT, and c) promotion of monoamine release into
the synaptic cleft (Seiden et al. 1993) (Fig. 1.2).

After amphetamine gains

presynaptic access by way of the monoamine transporter, it is thought to cause
direct inhibition of IC vesicular monoamine transporters (VMAT) that package DA
into vesicles.

This leads to an increase in IC levels of monoamine

neurotransmitters which cause reverse transport of the amines via cell
membrane transporters (Sulzer et al. 1993,1995). Increases in synaptic and EC
DA result in a dose-dependent manner in the presence of amphetamine (Solanto
et al. 2001). Amphetamine directly inhibits MAO, the enzyme that metabolizes
DA into 3,4-dihydroxy-O-phenylacetic acid (DOPAC) and homovanillic acid
(HVA). This leads to decreased formation of the oxidized metabolites of DA, NE,
and (serotonin) 5-HT. This occurs even at low doses leading to an increase in
DA release and a decrease in DOPAC production (Bowers and Hoffman 1984;
Elchisak et al. 1976; Imperato and Di Chiara 1984; Karoum et al. 1994;
Zetterstrom et al. 1988, 1983).

There are no known interactions between

amphetamine and COMT, another enzyme that metabolizes DA into 3methoxytyramine (3-MT). After the increases in EC and synaptic DA, elevated 3-
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MT levels result (Karoum et al. 1994). The physiological effect of increased
levels of EC DA from nigrostriatal DA neurons is feedback inhibition of DA
neuronal firing via stimulation of autoreceptors and second messenger systems
decreasing phasic DA release (Solanto et al. 2001) (Fig 1.2).
Studies have been done to investigate the cellular targets of amphetamine
and most data support interactions of amphetamine with catecholamine
transporters. Combinations of reserpine and amphetamine have been used to
evaluate the role of vesicles in causing the amphetamine-evoked release of DA.
The VMAT inhibitor, reserpine, was administered prior to amphetamine yielding
mixed results; some in vivo experiments supported no effect on DA release and
others reported reserpine blockade (Arbuthnott et al. 1990, Parker and Cebeddu
1986, Sabol et al. 1993). Some evidence support that vesicular stores of DA
contributed to increased synaptic DA levels after amphetamine administration
due to data indicating that TH is upregulated in the presence of reserpine or
amphetamine. It is also likely that most cellular DA is vesicular and must be
released to concentrate the cytoplasm in preparation for reverse transport
through the DAT (Fon et al. 1997; Mosharov et al. 2003). Cellular studies have
linked the roles of the DAT and the VMAT in causing amphetamine-induced DA
release. COS cells that expressed both VMATs and/or DATs were exposed to
amphetamine. These studies indicated that amphetamine caused DA release in
cells with the DAT, but significantly more release occurred in the presence of
cells containing VMAT or both VMAT/DAT. Finally, these data supported that no
DA release occurred from cells without VMAT or DAT (Pifl et al. 1995). Jones et
al. (1998) stimulated DA terminals to cause a stable baseline of DA release after
which amphetamine was added and a subsequent increase in DA resulted.
These data support that vesicular storage was altered in the presence of
amphetamine. Discussion is often raised due to information that supports de
novo synthesis of DA in the presence of amphetamine caused by upregulation of
TH activity (Kuczenski 1975). Other data indicate an interaction between MAO
and amphetamine that would decrease DA metabolite levels such as DOPAC.
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The DAT functions normally to maintain cytosolic DA, likely dependent on
a gating mechanism (Jardetzky 1966).

While a number of theoretical

explanations exist, prevailing ideas propose an asymmetric operation of the DAT
to more efficiently take up EC DA in efforts to concentrate cytosolic DA.
Alternatively, gradients of ions coupled with substrate and membrane potential
may cause the DAT to favor DA uptake (Sulzer et al. 2005). Interference of
these mechanisms by amphetamine leads to reverse transport of DA through the
DAT.

Previous literature discussed facilitated exchange diffusion as the

predominant model of amphetamine-induced reverse transport of the DAT based
on structural properties and their inclination to cause asymmetric substrate flux in
a one-for-one exchange pattern (Sulzer et al. 2005).

Facilitated exchange

diffusion was first studied in other systems looking at glucose transport and other
molecules (Stein 1967); however, more recent investigations have directly
attempted to measure the exchange properties of the DAT in the presence of
various substrates.

Jones et al. (1999) used reserpine-like compounds to

displace vesicular DA stores leading to increased levels of DA in the cytosol.
Increasing cytosolic levels of DA alone was not enough to cause efflux of DA,
and DAT uptake of amphetamine was necessary for reverse transport of the
DAT.

However, some reports have noted inconsistencies and support DA

release independent of amphetamine uptake.

For example, amphetamine

injected into large dopamine neurons of the pond snail caused reverse transport
of DA without transport of amphetamine (Sulzer et al. 1995). Therefore, other
conformational states of the DAT have been noted that would account for all
sources of amphetamine-dependent DA efflux. Patch-clamp recordings of cells
expressing the DAT have supported rapid, relatively increased current events
that indicate ion channel-like conductance of DA (Galli et al. 1996; Galli et al.
1998). A channel-like state of the DAT could allow a greater net flux of DA that
exceeds the amounts of DA released via reverse transport. Recently, recordings
from dopamine neurons and cells transfected with DATs supported channel-like
events that caused relatively transient (milliseconds), robust release of DA
molecules (Kahlig et al. 2005).
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Dextroamphetamine sulfate is commercially available for ADHD treatment
and has compared favorably with stimulants such as methylphenidate (Pelham et
al. 1990; Elia et al. 1993). Racemic amphetamine, the first available treatment
for children with behavioral disorders, is no longer commercially available.
However, Adderall® (75% D- 25% L-amphetamine) is a leading prescription
stimulant for children with ADHD. Data have supported that both enantiomers
can be more effective in treating ADHD than the other, dependent on different
subtypes of ADHD patients (Arnold et al. 1972, 1976). Other data support that
the dextro- isomer caused greater presynaptic release of DA than the levoisomer (Taylor and Snyder 1970, 1971; Arnold et al. 1972, 1973, 1976; Phillips
and Fibiger 1973; Segal 1975) while the levo- isomer has shown greater effects
on behavioral measures in rats in comparison to D-amphetamine (Segal 1975).
Further discussion of amphetamine enantiomer-dependent effects will occur in
Chapters 3, 4, and 5.
Methylphenidate
From the mid 1980’s until now, methylphenidate (Ritalin®) topped market
sales as one of the most prescribed stimulants for ADHD pharmacotherapy
(Patrick and Markowitz 1997). Due to increased incidence of side effects with Damphetamine and a dosing schedule that corresponded with school hours,
methylphenidate became a mainstay for ADHD treatment.

The use of

methylphenidate increased five-fold in the early 1990s due in part to clinical
diagnostic guideline revisions but not without growing concerns regarding its
recreational abuse (Diller 1996).
The majority of methylphenidate used clinically contains a racemic form of
50:50 threo-R,R(+)- and threo-S,S(-)-isomers, and data support that the
catecholaminergic effects of racemic methylphenidate are attributed to the active
threo-R,R (+)-stereoisomer (Patrick et al. 1987; Srinivas et al. 1992). Studies to
assess the necessity for the costly removal of the (-) isomer have provided data
to support that both the therapeutic and adverse side effects are attributable to
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the active (+)-isomer. (-)Methylphenidate has been found to penetrate the brain
following systemic metabolism and may interact with ethanol to form the
metabolite ethylphenidate (Patrick et al. 2005). While ethylphenidate is known to
be active in the CNS, its pharmacological effects are uncertain (Markowitz et al.
2000).

Due in part to this and other factors, a new separation of the

methylphenidate isomers has recently been approved in an immediate release
formulation and can be administered at one-half the dose of the racemic mixture
(Patrick et al. 2005).
The attributed decrease of ADHD symptoms when using methylphenidate
appears

to

be

dependent

on

the

facilitation

of

catecholaminergic

neurotransmission similar in some ways to amphetamine. Methylphenidate binds
selectively to the DAT or NET with high affinity (Schweri et al. 1985; Gatley et al.
1996) and blocks the synaptic clearance of impulse-released DA and NE leading
to EC neurotransmitter accumulation (Fig. 1.2). In a study of the striatum in
baboons, methylphenidate was shown to bind to the DAT, and (+)-isomer caused
the most potent DA accumulation in the rat striatum (Ding et al. 1994; Aoyama
1994, 1996).

Similarities to cocaine have been noted as methylphenidate

competes with cocaine for DAT binding in the striatum to accumulate EC DA
(Volkow et al. 1995; Gatley et al. 1996).
Methylphenidate is primarily thought to interrupt normal DA function by
blocking the DAT from uptake of impulse-dependent release of DA differing from
the effects of amphetamine that have been shown to trigger DA release through
the DAT (Fig 1.2).

Studies were done to determine the source of accumulating

DA after methylphenidate.

Reserpine, an agent that disrupts vesicular

membranes, attenuated DA release following treatment with methylphenidate
(Braestrup 1977; Patrick and Markowitz 1997).

Reduction of a newly-

synthesized pool of DA via inhibition with α-para-methyl-tyrosine decreased DA
release caused by amphetamine but not methylphenidate (Patrick and Markowitz
1997). Taken together, most of the literature support postsynaptic dopaminergic
agonistic activity as a key component of eliciting a response to methylphenidate.
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The Dopamine Transporter: Regulation of Stimulant Effects
Although some debate exists, immunohistochemical studies of the DAT
have supported that this catecholamine transporter protein can exist outside of
the synapse (Nirenberg et al. 1996, 1997a, 1997b; Hoffman et al. 1998; Squire et
al. 2003; Cragg and Rice 2004). Conclusions from these studies have discussed
that the predominant role of the DAT is to accumulate DA which has diffused
from the synaptic cleft.

Additionally, studies of DAT knockout mice have

supported decreased DA clearance and a complete loss of autoreceptormediated tone (Jones et al. 1999). Without the DAT, intraneuronal DA levels are
decreased leading to attenuated feedback inhibition of TH and subsequent
synthesis and release of DA (Gainetdinov et al. 1998).
The stimulants that we tested and their effects in the striatum are primarily
regulated by the DAT. Amphetamine analogues: methylphenidate and cocaine
are thought to block the DAT to increase synaptic and extracellular levels of DA.
The DAT constitutively cycles from the cell membrane to the intracellular milieu
where it is ultimately degraded or undergoes recycling and returns to the cell
membrane (Daniels and Amara 1999; Loder and Melikian 2003). In addition,
recent evidence has supported substrate induced effects on DAT function and/or
trafficking (Melikian and Buckley 1999; Fleckenstein et al. 1999; Kahlig et al.
2005; Gulley and Zahniser 2003; Saunders et al. 2000; Johnson et al. 2005; Little
et al. 2002; Daws et al. 2002; Cass et al. 1993a). Pharmacological interactions
with DA release, DAT function, and/or trafficking are theoretically believed to be
the underlying basis for addictive properties and likely therapeutic activity. Table
1.1 provides a summary of the effects of DAT substrates on subsequent DAT
function and availability after acute and chronic exposure.
Pharmacological interactions of stimulants and the DAT have been shown
to be substrate dependent. The endogenous substrate for the DAT, DA, has
been shown to cause changes in surface expression and/or DAT function. Data
have supported decreased DAT clearance abilities after repeated, rapid DA
applications (Gulley et al. 2002) and increased localization of the DAT to the
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cytosol (Saunders et al. 2000). Finally, DA has been shown to indirectly cause
upregulation of surface DAT by stimulating D2R autoreceptors that upregulate DA
clearance (Parsons et al. 1993; Cass and Gerhardt 1994; Rothblat and
Schneider 1997; Dickinson 1999; Hoffman et al. 1999; Mayfield and Zahniser
2001).

Acute amphetamine administration caused a reduction of transport

capacity thought to be due to intracellular DAT trafficking (Fleckenstein et al.
1999; Saunders et al. 2000); however, some reports support that amphetamine
initially caused upregulation to the cell surface prior to causing internalization
(Johnson et al. 2005). Other studies support substrate-dependent differences in
DAT conformation that differentially allow DA to pass through via formation of a
pore versus the constitutive state, an alternating access gate (Kahlig et al.
2005). Alternately, drugs thought to predominantly inhibit reuptake of DA by the
DAT, such as cocaine and methylphenidate, have opposite effects on DAT levels
and upregulation of the DAT to the cell surface has been supported (Daws et al.
2002; Little et al. 2002). Additionally, studies of DAT surface expression have
supported inconsistencies between the effects of chronic and acute exposure of
amphetamine isomers, methylphenidate, and cocaine. For example, while acute
cocaine exposure caused upregulation of DATs to the cell surface, chronic
cocaine has been shown to cause decreased levels of functional plasma
membrane DATs (Benmansour et al. 1992; Cass et al. 1993a; Jones et al. 1996;
Fleckenstein et al. 1999).
We hypothesized that differential effects of the stimulants we tested could
be attributed to differential regulation of the DAT caused by the amounts of DA
released and/or interactions with the DAT. The methodologies that we employed
for our studies are predominantly thought to provide a means for in vivo
monitoring of the function of cellular machinery involved in DA release and
uptake such as the DAT. The DA release signals we present in Chapters 3 and
4 represent the effects of amphetamine isomers as they cause reverse transport
of DA release (measures of rise time) and then blockade and/or down regulation
of DAT function and location (measures of 80% decay) (See Chapter 2 Figure
2.1).
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Rationale of Specific Aims
Upon initial review of the body of literature describing differences between
D- and L- amphetamine, it is evident that most clinical and scientific studies were
carried out in the 1970s. These studies were inconclusive and, in some cases,
the extension was made that either enantiomer could be helpful in decreasing
ADHD symptoms. Since the 1970s, a majority of the literature has focused on
methylphenidate in terms of its clinical use, and amphetamine in terms of abuse.
Due to the historical nature of safety and efficacy of amphetamine, it has largely
been ignored in terms of mechanistic interactions with catecholaminergic
signaling.

As the number of stimulants prescribed per month continues to

increase, it is important to build upon the data collected over two decades ago
using sensitive techniques with high resolution to examine target effects and
more efficient ways of causing a clinical effect. Additionally, the neurochemical
effects of the D- and L-amphetamine isomers have remained difficult to identify
and replicate (Popper 1994).
The dextro- isomer has been estimated to be at least two times more
potent in vivo in causing stereotypies in rats than the levo- isomer (Taylor and
Snyder 1970). Harris and Baldessarini (1973) present data that supported a
four-fold difference in potency of D-amphetamine versus L-amphetamine as
measured using in vitro DA uptake studies.

Sprague-Dawley rats trained to

discriminate between levers in response to drug-induced physiological states,
self-administered both amphetamine enantiomers in two different studies (Jones
et al. 1974; Yokel and Pickens 1973). However, data from these studies support
that it took greater amounts of L-amphetamine to equal the behavioral responses
induced by a smaller dose of D-amphetamine.

Studies completed in mice

assessing L-amphetamine and D-amphetamine potentiation of locomotor activity
support increased potency of D-amphetamine (Stromberg and Svensson 1975).
Additionally, the L-amphetamine dose-response curve displayed biphasic
properties that support stimulation of locomotor activity at high doses while
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depression of activity occurred at low doses (Stromberg and Svensson 1975).
The most recent study conducted investigated differences in D- and Lderivatives and their effects on a canine model of narcolepsy (Kanbayashi et al.
2000).

The data from the Kanbayashi et al. (2000) study indicate that D-

amphetamine was two times more potent in increasing wakefulness, while the
enantiomers were similar in effects on rapid eye movement.

Microdialysis

studies revealed similarities in the overall effect of maximum DA overflow with Lamphetamine, reaching a DA overflow plateau over a longer time period
(Kanbayashi 2000). Finally, the distribution kinetics of D- and L- amphetamine
were studied after intravenous administration of racemic amphetamine to
Sprague-Dawley rats and these data support similar isomer terminal half-lives
(Hutchaleelaha et al. 1994).
Clinical studies have provided evidence that D-amphetamine was superior
to racemic amphetamine in terms of improvement in ratings of target symptoms
(Gross 1976). Smith and Davis (1977) suggested that L-amphetamine was only
half as potent as D-amphetamine in causing feelings of euphoria.

Taken

together, these data support enantiomer-dependent differences in molecular,
behavioral, and clinical effects. Conversely, other studies support similarities
between isomers of amphetamine.

Arnold et al. (1972) administered L-

amphetamine and D-amphetamine to hyperkinetic children (the clinical diagnosis
for ADHD at the time) and determined that both were significantly more effective
than placebo in influencing parent-teacher ratings. Data from this study indicate
that

D-

and

L-amphetamine

targeted

symptoms

of

hyperactivity

and

aggressiveness, while D-amphetamine also decreased inattentiveness (Arnold et
al. 1972). Arnold et al. (1976) suggested in a later study that L-amphetamine
was a useful drug option for treatment of minimal brain dysfunction (the clinical
diagnosis for ADHD at that time), and the behavioral outcomes of D- and Lisomers were similar. Prior to these studies, a clinical study assessed and found
no clinical differences between Benzedrine® (50:50 D,L- amphetamine) and
Dexedrine® (D-amphetamine) (Bradley 1950). These clinical studies, conducted
to examine stimulant medications with different amphetamine isomers, have
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provided information to support the use of drugs containing L-amphetamine while
others have provided equivocal results. These data were collected at a time
when the symptoms of the disorder were not well characterized.

Likewise,

participant exclusion/inclusion criteria were not always similar, and the number of
participants included for statistical analysis was not always optimal.
Based on the rise and fall of treatment alternatives for ADHD, the market
has seen racemic amphetamine (Benzedrine®) come and go, replaced by a
separated D-amphetamine (Dexedrine®), paralleled in the most recent years with
the return of a mixture containing both enantiomers (Adderall®, mixed salts
amphetamine). Even though Adderall® currently leads the ADHD prescription
market, no studies have been published addressing the components and the
chosen ratio of D- and L- amphetamine. Originally marketed to be longer-lasting
and the only ADHD drug that could eliminate the need for “in-school” dosing,
Adderall® maintains a sparse collection of data that would support or reject this
hypothetical conjecture (Popper 1994). Unpublished data from the Richwood
Pharmaceutical Company (1997) supported a differential rate of absorption and
an associated increased efficacy due the activity of the four Adderall® salts not
found in other stimulants. While no animal studies exist, a few clinical studies
sponsored by Shire Pharmaceuticals have addressed the claims of Adderall’s®
longer lasting activity. An initial study by Swanson et al. (1998) found data to
support rapid improvements in teacher ratings that occurred within 1.5 hours
after administration that lasted throughout the day. The peak time of effects and
duration of action increased dependent on dose (Swanson et al. 1998). In a
comparison of Adderall® versus Ritalin® (methylphenidate), Adderall® continued
to improve measures taken at time points of the day when the effects of a single
dose of Ritalin had dissipated (Pelham et al. 1999). This study collected data
that consistently supported the 1:2 dosing ratio between D-amphetamine and
methylphenidate, and suggested that Adderall® is at least twice as potent in
acutely improving the behavior and academic productivity of children with ADHD
(Pelham et al. 1999). An independent study of high relevance to the data we
present is a recent clinical study that compared Adderall® versus extended16

release and immediate-release D-amphetamine sulfate in a double-blind,
placebo-controlled paradigm. James et al. (2001) took dependent measures of
classroom behavior, recreational activity, parent observation, locomotor activity,
and adverse effects.

These data revealed similarities between immediate-

release D-amphetamine and Adderall® while extended-release D-amphetamine
displayed more sustained effects on most measures.

Specifically, Adderall®

significantly reduced locomotor activity relative to D-amphetamine (immediateand extended-release) with effects that lasted longer than the other drugs.
Weight loss occurred with all three drugs tested in this study; however, Adderall®
did not cause decreased sleep duration (James et al. 2001).
Basic science studies with increased temporal and spatial resolution, and
techniques with high sensitivity are necessary to further examine the properties
of amphetamine enantiomers in vivo. The studies completed for this dissertation
are the first studies to characterize the effects of locally applied, clinically
relevant, commercially available stimulants and their components on DA
neurotransmission. These studies made use of local drug applications to
eliminate drug pharmacokinetic issues from the study. Due to this, drugs were
applied in low levels to approximate clinically relevant levels of ADHD
medications based on theoretical tissue dilution (voltammetry) and percent
recovery (microdialysis) (Gerhardt and Palmer 1987; Shader et al. 1999; Solanto
et al. 2001).

At this date, there are no in vivo animal studies of Adderall®

regarding measures of neurotransmitters or behavior.

In general, we

hypothesize that amphetamine analogs differ in their ability to cause DA release
and differentially alter DA uptake.

This hypothesis was studied using the

following specific aims:
Specific Aim 1: Is it possible to reliably measure DA release signals evoked by
amphetamine

isomers

at

maximally

effective

concentrations

related

to

therapeutic levels using high speed chronoamperometry? Do locally applied
amphetamine isomers differentially affect DA release signals as measured by in
vivo voltammetry? Since amphetamine isomer associated differences have been
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noted in the clinic, it is possible that in vivo differences will be visible in DA
neurotransmission in the striatum and nucleus accumbens of the rat brain,
regions implicated in human studies of ADHD.
Specific Aim 2: Adderall® has been noted by clinicians to be a long-acting
stimulant treatment for ADHD and data have supported that Adderall® decreases
symptoms of hyperactivity over a longer time period than D-amphetamine.
Therefore, do local applications of Adderall® cause differential effects on DA
release signals compared to D-amphetamine at lower, clinically relevant levels of
drug?
Specific Aim 3:

Using techniques (microdialysis and HPLC) that allow for

increased sensitivity to measure lower levels of analytes in vivo, will comparisons
of stimulant concentration-response curves support differences in efficacy and
potency?
Summary of Experiments
Single isomer compounds such as dextroamphetamine (Dexedrine),
dexmethylphenidate

(Focalin®),

and

racemic

compounds

such

as

methylphenidate (Ritalin®) and mixed-salts amphetamine (Adderall®) are the
most current medications available for treating the symptoms of ADHD. The
drug Adderall® is made of an approximate combination of 25% L-amphetamine
and 75% D-amphetamine and has been marketed since the 1990s as a first-line
stimulant treatment for ADHD. Following clinical use of Adderall®, Benzedrine®
(D,L-amphetamine), and D-amphetamine, differences have been noted in
regards to their individual effects in decreasing symptoms. Potential differences
at the level of neurotransmission have not been characterized between these
treatment options. To investigate any differences in amphetamine isomers, high
speed chronoamperometry was used allowing for measures of real-time DA
release signals in Chapter 3.

Using Nafion®-coated, single carbon fiber
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microelectrodes, amphetamine-induced DA levels and signal time courses were
measured in the striatum and nucleus accumbens core of anesthetized male
Fischer 344 rats. To study the individual effects of amphetamine isomers on DA
neurotransmission, low concentrations of drugs were administered locally via
pressure ejection through a micropipette.
For these studies, the L-amphetamine in a 50:50 D,L-amphetamine
solution did not cause increased release of DA; however, it did seem to affect DA
release signal kinetics. Signals evoked by D,L-amphetamine had significantly
faster rise and decay times in both the striatum and nucleus accumbens core.
After local applications of L-amphetamine alone, evoked DA signals were not
significantly different in measures of amplitude from D-amphetamine evoked DA
release signals; however, these L-amphetamine-evoked DA release signals
displayed the rapid signal kinetics seen with D,L-amphetamine. The results of
these studies supported the hypothesis that amphetamine isomers differentially
cause release of DA in the striatum and nucleus accumbens core. These data
support the possibility that L-amphetamine may have unique actions on the DAT,
and the way in which reverse transport of DA occurs following administration of
amphetamine.
Following the studies discussed in Chapter 3, we then tested Adderall® in
the 75% D: 25% L-amphetamine combination making use of all four
amphetamine salts to make comparisons with D-amphetamine and D,Lamphetamine at lower, more clinically relevant concentrations in Chapter 4.
During the time in which these studies were carried out, prescriptions and sales
of Adderall®, for the first time, were similar to those of methylphenidate.
Additionally, these are the first data generated from in vivo measures of
Adderall® since its introduction to the market.

The technique of high speed

chronoamperometry using Nafion®-coated, single carbon fiber microelectrodes
was used to study amphetamine-evoked DA release produced by Adderall®, Damphetamine, or D,L-amphetamine in the striatum of anesthetized male Fischer
344 rats. The amphetamine solutions were locally applied from micropipettes by
pressure ejection. Local applications of Adderall® resulted in significantly greater
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DA release signal amplitudes and prolonged time courses compared to Damphetamine and D,L-amphetamine. These are the first in vivo data to support
the hypothesis that the combination of amphetamine enantiomers and salts in
Adderall® have effects on DA release, which result in increased and prolonged
DA release compared to D- and D,L-amphetamine.
While the results discussed in Chapter 3 and 4 made use of second-bysecond recording methods to determine the effects of acute applications of
stimulants on DA release, Chapter 5 describes studies completed using a
technique having greater sensitivity to detect lower levels of analyte. We tested
the hypothesis that differential stimulant concentration-response curves of DA
and metabolites would result dependent on the amount of amphetamine isomer
present. In addition, we predicted that DA overflow caused by methylphenidate
would differ from amphetamine.
amphetamine,

and

For these studies, complete Adderall®, D-

methylphenidate

concentration-response

curves

were

determined across theoretical subtherapeutic to abuse levels of drug. Finally,
comparisons

were

made

with

“Reverse

Adderall”

containing

25%

D-

amphetamine and 75% L-amphetamine. The technique of reverse microdialysis
was used to study local drug-evoked DA release accumulation in the striatum of
anesthetized male Fischer 344 rats.

These data support a D-amphetamine

concentration-response curve of DA with double plateaus.

These resulting

concentration-response curves provide insight into functional properties of the
DAT and/or specific release of DA stores. Additionally, DA levels after local
applications of methylphenidate were similar to those caused by amphetamine.
These methylphenidate data likely resulted due to reuptake blockade of a small
amount of impulse-dependent DA being released under anesthesia. However,
these data may also support a DA releasing effect of methylphenidate.
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Table 1.1 DAT and Substrate Interactions
DAT Substrate

Effects on the DAT (Acute unless otherwise noted)

Dopamine

● Decreased transporter currents in vitro (Gulley and

Zahniser 2003)
•

Rapid applications of DA decreased DAT clearance
abilities in vivo (Gulley et al. 2002)

•

Increased localization of DATs to cytosol in vitro
(Saunders et al. 2000)

•

Inhibited channel mode of the DAT in vitro (Kahlig et al.
2005)

Amphetamine

●

Rapidly

decreased

DAT

function

and

caused

intracellular accumulation and internalization of an
active DAT in vitro, in vivo (Kahlig et al. 2004; Saunders
et al. 2000; Fleckenstein et al. 1999)
•

Induced a channel-like DAT in vitro (Kahlig et al. 2005)

•

Initially recruited DATs to the plasma membrane to
cause DA efflux followed by internalization after
continued exposure in vitro (Johnson et al. 2005)

Methylphenidate

●

Increased DAT density and caused upregulation of
DATs to the plasma membrane in vitro (Little et al.
2002)

•

Chronic use was followed by decreased levels of DATs
density in the rat striatum but not nucleus accumbens
(Izenwasser et al. 1999; Moll et al. 2001)

Table 1.1 Continued Next Page
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Table 1.1 Continued
Cocaine

●

Increased DAT density and caused mobilization of the
DAT to the cell surface in vitro (Daws et al. 2002; Little
et al. 2002)

•

Functional upregulation and increased clearance of the
DAT in vitro, in vivo (Cass et al. 1993, Sabeti et al.
2002; David et al. 1998; Zahniser et al. 1999; Zahniser
and Sorkin 2004)

•

Chronic exposure caused down regulation of DAT
function and substrate binding in vivo, in vitro
(Benmansour et al. 1992; Cass et al. 1993; Jones et al.
1996; Fleckenstein et al. 1999)

•

Following cessation of chronic use, increased DAT
levels (Malison et al. 1998)
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Figure 1.1 Dopamine Synthesis and Clearance
The precursor L-tyrosine is converted to dihydroxyphenylalanine (DOPA) which
reacts with aromatic acid decarboxylase to form DA. DA can be packaged in
vesicles for storage until depolarization leads to vesicular fusion with the plasma
membrane and DA is released. DA clearance results from (a) metabolism via
COMT into 3-MT (b) uptake by the DAT and (c) intracellular degradation via
enzymes such as MAO into DOPAC. Extracellular levels of DA interact with DA
receptors (autoreceptors and postsynaptic receptors) resulting in presynaptic
effects and postsynaptic down regulation of further DA release.
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Figure 1.2 Theoretical Targets of Amphetamine Activity
Amphetamine (X) theoretically interacts with multiple cellular targets.

Data

support that DA gains presynaptic access through the DAT where it can block
VMATs and cause emptying of vesicles to increase cytoplasmic levels of DA.
Interactions with MAO have been noted leading to decreased levels of DOPAC.
Finally, due to increased cytoplasmic levels of DA and/or interactions with
amphetamine, the DAT begins to work in reverse fashion to allow DA to exit the
cell. Amphetamine subsequently blocks future reuptake or normal function of the
DAT

and

undergoes

conformation

changes

and/or

internalization.

Methylphenidate ( ) is thought to block the reuptake of Ca2+-dependent DA
released through the DAT, causing DA release different from the activity of
amphetamine.
Copyright © Barry Matthew Joyce 2006
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Chapter 2: Materials and Methods
The Fischer 344 Rat as an Animal Model of Normal Dopaminergic Function
Since the primary purpose of these studies was to assess mechanistic
properties using low levels of stimulants, we chose normal male Fischer 344
(F344) rats as a model of the mammalian central nervous system. The F344 is
an inbred strain of rat lending to increased genetic homogeneity. While some
variations still exist between rats within this strain, the central nervous system
lacks the heterogeneity of other outbred strains (Masoro 1990). Additionally, any
variations between these rats are thought to mimic the variations present in the
normal human population. While F344 rats, in general, show a constant increase
in body weight and weight fluctuations between individual rats do not occur when
fed ad libitum, they are also known to be a rat strain most related to human aging
(Austad 1997; Stanford et al. 2001). This rat strain was also chosen due to the
cost effective nature of their inclusion in these studies and availability. Data have
supported that stimulants work to improve attention via maintenance of alertness
in normal, healthy subjects (Syed et al. 2005), and the success of stimulant
treatments for ADHD to decrease hyperactivity and increase attention is known
to be highly variable from one patient to another (Rapoport et al. 1978; Elia et al.
1991). Therefore, in characterizing the effects of stimulants on dopaminergic
neurotransmission, it was important to choose a non-diseased rat model. Finally,
3-6 month old rats were chosen for these studies to mimic developmental
similarities of a young human population inclusive of the majority of patients
receiving stimulants for ADHD. Additionally, this age group of the F344 rat is
considered to be developmentally mature which would decrease variations in
brain physiology.

Finally, the F344 rat has been extensively used in our

laboratory due in part to small variations in brain size across age levels allowing
for more accurate targeting of stereotaxic coordinates.
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Urethane as Anesthesia for Electrochemical Recordings and Microdialysis
in the Living Fischer 344 Rat Brain
Intraperitoneal (i.p.) injections of 25% urethane prepared in 0.9% saline
and administered at 1.25 g/kg were given to each rat. Each awake rat was
restrained and administered 0.7 ml of 25% urethane for an initial injection. After
15 minutes, the weight of the rat was determined and the final dosing amount
was calculated. The remainder of dosing was divided evenly among the next two
injections both 15 minutes apart. After 45 minutes from initial dosing, a response
to a toe pinch was determined. If no response resulted from the toe pinch, the
experiment was carried out as described below. Sabeti et al. (2003) recently
studied the effects of different anesthesias on measures of dopamine (DA)
signals recorded in awake, behaving animals until they were completely
anesthetized. The results of these studies support that urethane only minimally
affected DA release and signal decay in comparison to chloral hydrate and
ethanol (Sabeti et al. 2003).
In Vivo Chronoamperometric Recordings
Animal Preparation for Acute Electrochemical Recordings
The F344 rats were anesthetized as described above and placed into a
stereotaxic frame (Kopf, Tujunga, CA) with the incisor bar set at -2.3 mm. Body
temperature was maintained at 37º C as indicated by a rectal thermometer while
rats rested on a heating pad (Braintree Scientific, Braintree, MA). A cross-type
incision was made over the medial portion of the skin between the rat’s ears and
retracted in place using bulldog clips to anchor the movement of the skin during
surgery.

The skull overlying the medial cortex was removed bilaterally for

recordings in striatum and nucleus accumbens where noted.

Working

microelectrodes were inserted bilaterally into the striatum (AP + 1.0 mm, ML +/2.3 mm, DV -4.0 to -6.0 mm; 0.5 mm increments). Reference electrodes (200µm
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o.d., Ag/AgCl) were placed 8-10 mm posterior to bregma and 0.5 to 1.0 mm
lateral to midline and were cemented in place using dental acrylic. All stereotaxic
coordinates were determined with respect to bregma using the atlas of Paxinos
and Watson (1998).

All procedures were performed in accordance with the

National Institutes of Health Guidelines for the Care and use of Mammals in
Neuroscience and Behavioral Research (2003) and were approved by the Animal
Care and Use Committee of the University of Kentucky. Figure 2.4 shows a
F344 rat prepared for in vivo electrochemical recordings.
Electrochemical Microelectrodes
Single carbon-fiber type electrochemical working microelectrodes (30 µm
o.d.) were used to measure DA release signals (Fig. 2.6). The microelectrodes
(Quanteon, L.L.C., Nicholasville, KY) were pre-dried at 200 ºC prior to coating
with Nafion® (5% solution, 1-3 coats, Aldrich Chemical Co., Milwaukee, WI).
They were dipped in Nafion® solution and dried at 200º C for 5 minutes between
each coat (Fig. 2.7). Prior to use, all microelectrodes were calibrated in vitro to
determine their selectivity, sensitivity, and reduction/oxidation current responses
to DA. For use in these studies, microelectrodes had an average selectivity of
>900:1 for DA over 3,4-dihydroxyphenylacetic acid (DOPAC) or ascorbic acid.
Each microelectrode displayed linear responses to DA additions up to 8 µM
(Hoffman and Gerhardt 1999; Gerhardt and Hoffman 2001). Reduction/oxidation
current ratios averaging between 0.5 to 0.7 were exhibited, indicating that the
microelectrode was detecting DA and not serotonin (5-HT) or ascorbic acid
(Gerhardt and Hoffman 2001; Gerhardt and Burmeister 2000).
detection for DA was typically 25 nM.

The limit of

Refer to Figure 2.1 for further detail

regarding the reduction/oxidation current ratios and performance of the
microelectrodes.
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Electrochemical Instrumentation
The microelectrodes were connected to a headstage (Quanteon, L.L.C.
Nicholasville, KY) with a gold-plated amphenol (wire-crimp, Mill-Max®, Oyster
Bay, New York). The headstage was connected to a high-speed Pentium-IV
microcomputer- controlled instrument, the FAST-12 (Fast Analytic Sensing
Technology, Quanteon, L.L.C. Nicholasville, KY) and chronoamperometric
measurements (5 Hz) were performed. An oxidation potential was applied (+0.55
V; 0.0V resting versus Ag/AgCl reference) to the working microelectrode. The
potential of the working microelectrode was changed relative to a stable,
Teflon™ coated, silver wire electroplated in 1- M HCl saturated in NaCl (Ag/AgCl
Reference Electrode). The resulting oxidation current and subsequent reduction
current from the microelectrodes were integrated during the final 80% of each
100-ms pulse. Both oxidation and reduction currents were continually recorded
and averaged to 1 Hz. In all recordings, reverse current ratios (redox ratios)
were used to further confirm the detection of DA by the microelectrode measures
(Gerhardt and Hoffman 2001; Gerhardt and Burmeister 2000).
Drugs for Use with In Vivo Electrochemical Recordings
Urethane, D-amphetamine and D,L-amphetamine were obtained from
Sigma (St. Louis, MO). The L-amphetamine isomer was obtained from the NIHNIDA/Division of Neuroscience and Behavioral Research (Bethesda, MD). The
four components of Adderall®, D-amphetamine saccharate, D,L-amphetamine
aspartate, D-amphetamine sulfate, and D,L-amphetamine sulfate, were obtained
from Shire Pharmaceuticals (Hampshire, Chineham, England). DA and DOPAC
were obtained from Aldrich (Milwaukee, WI). All drug solutions were prepared in
0.9% saline and adjusted to a final pH of 7.4
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Pressure Ejection Coupled to In Vivo Electrochemical Recordings
To circumvent the use of parental drugs to alter monoaminergic function
and to directly study the extracellular regulation of DA, local application of drugs
coupled with in vivo electrochemical recordings was used to study drug-induced
release of DA (Hebert and Gerhardt 1999; Hoffman and Gerhardt 1999). Singlebarrel glass micropipettes (Kopf Puller, Tujunga, CA) (1 mm outer diameter, 0.58
mm inner diameter, AM systems, Inc., Everett, WA) with an inner tip diameter of
7-11µm were attached to Nafion®-coated carbon-fiber microelectrodes with sticky
wax (Kerr, Orange, CA) so that the tip of the electrode and micropipette were in
the same plane and measured 250 µm apart.
The volume of applied drug was kept constant at 500 nl and was
measured using a dissection microscope fitted with a calibrated reticule (1 mm
change=25 nl of fluid) (Cass et al. 1992, 1993a; Friedemann and Gerhardt 1992).
The amounts of drugs applied in Chapter 3 were determined as: 2 nanomoles Damphetamine, 4 nanomoles D,L-amphetamine, 2 nanomoles D,L-amphetamine
and 2 nanomoles L-amphetamine. For Chapter 4, Adderall®, D,L-amphetamine
or D-amphtamine solutions were applied in the following amounts (0.68
nanomoles Adderall®, 1 nanomole D,L-amphetamine, and 0.5 nanomoles Damhetamine). For the data presented in Appendix 1, high concentrations of Damphetamine and Adderall were selected for use and were applied in the
following amounts 2 nanomoles D-amphetamine and 2.72 nanomoles Adderall®
(West et al. 1999; Shader et al. 1999; Kuczenski and Segal 2001; Solanto et al.
2001). The data from Chapter 3 support that L-amphetamine only regulates the
time-course of D-amphetamine and does not contribute to the potency of an
amphetamine solution. Therefore a constant 0.5 nanomoles of the Damphetamine isomer were applied in all drug treatments in Chapter 4 in order to
investigate the effects of differing amounts of L-amphetamine.
The stimulant concentrations used for pressure ejection were chosen
based on the necessary amount of stimulus needed to give consistent and
comparable DA responses. It is difficult to accurately predict the dilution factor of
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a locally applied drug to the brain tissue at varying depths. We estimate that our
drug solutions used in Chapter 3 (40-400 μM) were in the upper range of
effective concentrations of plasma levels determined after clinical use of
stimulants (10-50 μM)(West et al.

1999; Shader et al. 1999; Gerhardt and

Palmer 1987; Solanto et al. 2001). The concentrations were then decreased for
the studies described in Chapter 4 and were estimated to be in the therapeutic
range for ADHD.
Stimulant-Evoked Release of DA
Electrochemical measurements were performed at 5 Hz to establish a
baseline response. After achieving a steady state signal (usually in 5 minutes),
the effects of local applications of the amphetamine solutions were studied
(Gerhardt et al. 1986,1987; Gerhardt and Palmer 1987; Cass et al. 1993b;
Luthman et al. 1993). The drug solutions were applied over a 20 second period
to minimize any local dilution of DA release signals by the drug solutions. A
typical amphetamine-induced DA release signal is shown in Figure 2.1. After
returning to baseline, the electrode assembly was lowered an additional 0.5 mm,
and the drug solution was ejected at the next depth. Typically, six- eight signals
were recorded in the striatum (three signals in the nucleus accumbens) bilaterally
in the individual animals.
Histology After In Vivo Electrochemical Recordings
Following the recording sessions, rats were perfused with saline, followed
by 4% paraformaldehyde. The brains were subsequently removed, frozen with
dry ice, sliced into 50-µm coronal sections, and stained with Cresyl Violet stain
for histological evaluation of probe placement and recording tracks. Data from
histologically confirmed correct placement of microelectrodes into the striatum
(and nucleus accumbens) were used for data analysis. No data were rejected
based on incorrect placement of microelectrode assembly in these studies.
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Figure 2.2 shows a typical slice from the striatum of a F344 rat following after an
in vivo chronoamperometric recording session. This technique is noted to be
minimally invasive relative to other in vivo recording techniques, and greater
spatial resolution can be resolved due to the 30 μm outer diameter of the
microelectrode (Fig. 2.2).
Analysis of Data Collected Using In Vivo Voltammetry
We chose recordings with redox ratios indicative of predominant DA
signals (0.5-0.7) with signal amplitudes ≥0.05 µM DA for analysis of temporal
dynamics of DA release: rise times (TR) and 80% decay times (T80) (Fig. 2.1)
(Gerhardt and Hoffman 2001). The numbers of animals and recording signals for
each drug group in Chapter 3 for striatum were: D-amphetamine (n=7 animals,
28 recordings), D,L-amphetamine (n=7 animals, 34 recordings), 2 x D,Lamphetamine (n=7 animals, 40 recordings) and nucleus accumbens: Damphetamne (n=7 animals and 17 recordings), 2 x D,L-amphetamine (n=7
animals and 16 recordings), and D,L-amphetamine (7 animals, 21 recordings).
The number of animals used for the comparison of D- versus L-amphetamine
were n=9, 34 recordings and n=7 rats, 17 recordings in the striatum and n=16
and 4 rats in the nucleus accumbens respectively. For the studies completed for
Chapter 4, the following animals and signals were used for data analysis: D,Lamphetamine (n=10 animals, n=30 signals), Adderall® (n=10 animals, n=54
signals), and D-amphetamine (n=10 animals, n=42 signals). DA signals were
heterogeneous in nature, which is the normal distribution of DA signals in the rat
striatum (Friedemann and Gerhardt 1992).

Multiple recordings were taken

bilaterally at various striatal (and nucleus accumbens) depths in each animal and
each recording depth.

Therefore, to avoid artificially increasing degrees of

freedom and pseudoreplication by treating each recording independently, a
nested between-groups analysis of variance (MANOVA) was used (Hurlbert
1984; Salvatore et al. 2004).

SYSTAT’s Multivariate General Linear Model

(SYSTAT Software, Richmond, CA, USA) was used for statistical analysis while

31

all analyses were followed by Tukeys post-hoc comparisons.

Statistical

significance was defined as p<0.05.
Intracerebral Reverse Microdialysis Measures of Dopamine and Metabolites
Animal Preparation
The animals were prepared for study similar to the descriptions provided
earlier in this chapter. Differences in surgical procedures are described here.
After the retraction of the skin and tissue and exposure of the skull overlying the
striatum, a small craniotomy was placed in the right hemisphere only
(coordinates with respect to bregma: +1.0 mm AP, ±2.2 mm ML) (Paxinos and
Watson 1998). A microdialysis probe with a 2-mm membrane (CMA/11, CMA
Microdialysis, Stockholm, Sweden) (Fig. 2.9) was lowered into the striatum (6
mm below the cortical surface) and remained at this depth for the duration of the
experiment Fig. 2.5). 1000 μl gastight syringes (1001 LTN, Hamilton USA, Reno,
NV) containing dialyzing fluids were positioned in a syringe pump (KDS230, KD
Scientific, Holliston, MA) which was set at flow rate of 1 µl/min, chosen based on
desired percent recovery for striatum and the microdialysis probe membrane
length employed (Fig. 2.10). Syringes were connected to a liquid switch
(CMA/110, CMA Microdialysis, Stockholm, Sweden) that allowed for alternation
between treatments: artificial cerebral spinal fluid (aCSF) and aCSF + drug (Fig.
2.8). Teflon tubing (FEP tubing, 0.12 mm inner diameter, CMA Microdialysis,
Stockholm, Sweden) and tubing adapters (CMA Microdialysis, Stockholm,
Sweden) were used to establish all connections.
In Vivo Intracerebral Reverse Microdialysis
Following probe insertion, perfusion with aCSF (in mM: NaCl 123, KCl 3,
CaCl2 1, MgCl2 1, NaHCO3 25, NaH2PO4 1, and glucose 5.9) at a pH of 7.4 was
initiated. Samples were then collected at twenty minute intervals into a 0.2 ml
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microcentrifuge tube and injected into the HPLC-EC system.

The order of

administration for each of the drug solutions tested was as follows: samples 1-6
(aCSF), sample 7 (aCSF + amphetamine solution), samples 8-12 (aCSF).
Probe recoveries were collected using a standard solution with known
concentrations

of

dihydroxphenylacetic

DA,
acid

norepinephrine
(DOPAC),

(NE),

serotonin

Homovanillic

Acid

(5-HT),
(HVA)

3,4-

and

5-

Hydroxyindole Acetic Acid (5-HIAA). In order for a probe to be used in these
studies, an in vitro probe recovery of 10% ± 1 was required based on
methodological standards. Based on this exchange rate of 10-20%, seen for
molecules similar in size to amphetamine such as DA, NE, and 5-HT, we
determined the effective concentrations of stimulant drugs across a range of
starting concentrations. Stimulant concentrations were chosen to represent a
range of concentrations that included clinically relevant levels. Based on the
approximate exchange rate, solutions of aCSF only, 0.1 µM, 0.5 µM, 1 µM, 5 µM,
10 µM, 25 µM, 50 µM, 100 µM, 400 µM (for D-amphetamine, L-amphetamine,
methylphenidate, D,L-amphetamine, and cocaine), 533 µM (for Reverse Adderall
only), and 539 µM (for Adderall® only) were prepared via serial dilutions at a pH
of 7.4. Solutions were prepared for study and consisted of normal aCSF and
drug.

Prior to each experiment, 20 mM ascorbic acid was added to each

solution and solutions were aerated with 95% O2/5% CO2.

Solutions were

immediately added to individual 1000 μl gastight syringes.
Histology of the Striatum Following Intracerebral Reverse Microdialysis
Following each experiment, rats were intracardially perfused with 0.9%
NaCl solution followed by a 4% paraformaldehyde solution.

They were then

decapitated, and their brains were frozen, sliced on a cryostat, and stained with
Cresyl Violet. Probe placements were confirmed histologically. An example of a
brain section after a microdialysis experiment is shown in Figure 2.3.
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Analysis of Microdialysis Samples
HPLC analysis followed the methods described by Hall et al. (1989). The
low level detections of DOPAC, DA, 5-HT, NE, 5-HIAA, and HVA were performed
using an isocratic HPLC system (Beckman, Inc., Fullerton, CA) coupled to a
dual-channel

electrochemical

array

detector

(model

5300A,

ESA,

Inc.,

Chelmsford, MA), E1 = +0.35 mV and E2 = -0.25 mV, with an ESA model 5011A
dual analytical cell. The compounds of interest were separated with reversephase chromatography, using a C18 column (4.6 mm x 75 mm, 3 μm particle
size, Shiseido CapCell Pak UG120, Shiseido Co., LTD., Tokyo, Japan) with a pH
4.1 citrate-acetate mobile phase, containing 4% methanol and 0.34 mM 1octane-sulfonic acid and delivered at a flow rate of 2.0 ml/min. Peaks for the
analytes were identified by retention times from known standards.
Statistical Analysis of Analyte Levels in Microdialysis Samples
Data were collected from 5-6 animals per 10 drug concentrations (for
Adderall®, D-amphetamine, Reverse Adderall, and methylphenidate). Data were
collected for 5-6 animals for the highest drug concentration only for Lamphetamine, D,L-amphetamine, and cocaine.

The raw microdialysis values

were expressed as nM based on a 1 x 10-7 M mixed standard of known analytes
and concentration used to determine a percent recovery in vitro prior to use of
each probe. Outliers were excluded based on data falling outside of 2 standard
deviations from the mean. Concentration-response curves were constructed
based on the mean peak DA overflow concentration following the twenty minute
reverse microdialysis of each drug concentration. GraphPad Prism statistical
analysis software, version 4.0 (Prism, San Diego, CA, USA), was used to
determine the appropriate nonlinear curve fit and Log half maximal effective
concentration (EC50) of each drug. An initial one-way analysis of variance was
used to determine significance of DA overflow from the aCSF control. A second
one-way analysis of variance was used followed by post-hoc t-tests with
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Bonferroni’s corrections to compare DA following reverse microdialysis of
clinically relevant drug concentrations and maximum concentrations. Statistical
significance was defined as p<0.05.
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Figure 2.1 Typical Amphetamine-Evoked DA Release Signal
A representation of typical tracings of D-amphetamine-induced DA release
measured by high-speed (5 Hz) chronoamperometry is shown. The top signal
indicates the oxidation of DA and the bottom signal indicates the reduction
current. The measured reduction/oxidation (redox) ratio of this DA release signal
is characteristic of DA detection by the microelectrode.

Rise time (TR) is

indicated and defined by the total time required for the DA signal to reach the
indicated maximum amplitude. 80% decay time (T80) is a measure of the total
time required for the DA release signal to decay 80%. Inset: Measured redox
ratios of carbon fiber microelectrodes used for experiments. Prior to use of each
microelectrode, in vitro calibrations were completed to determine redox ratios
before insertion into the rat brain. The mean in vivo redox ratio was determined
by averaging ratios from amphetamine-induced DA recordings in multiple rat
brains. The in vivo and in vitro redox ratios are similar to those expected for DA
and notably different from recordings of 5-HT and ascorbate in vitro.
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Figure 2.2 Histological Preparation of a Rat Brain After Acute
Electrochemical Recordings
Following the recording session and perfusion of the rat, brains were removed,
frozen, sectioned, and stained with Cresyl Violet to check accuracy of probe
placement. Arrow denotes probe track of a carbon fiber microelectrode coupled
to a micropipette in the striatum (Chapters 3 and 4).

The tip of the

microelectrode, with an outer diameter of 30 µm, was waxed 250 µm from the tip
of a micropipette (inner diameter of 10 µm). The histology above shows little
damage after a complete experiment.
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Figure 2.3 Histological Preparation of Rat Brain Striatum After a
Microdialysis Experiment
Following the microdialysis session and perfusion of the rat, brains were
removed, frozen, and sectioned on a cryostat and subsequently stained with
Cresyl Violet to check accuracy of probe placement. Arrow denotes probe track
of the microdialysis probe in the striatum (Chapter 5). The membrane of the
microdialysis probe had an outer diameter of 240 µm and was 2 mm in length.
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Figure 2.4 Fischer 344 Rat Prepared for In Vivo Voltammetric Recordings
3-6 month old F344 rats were anesthetized with 25% urethane and carbon fiber
microelectrodes were lowered into the striatum for recordings of DA release
signals.

Figure 2.5 Fischer 344 Rat Prepared for Intracerebral Reverse Microdialysis
3-6 month old F344 rats were anesthetized with 25% urethane and CMA
microdialysis probes were lowered into the striatum for microdialysis of aCSF.
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Figure 2.6 Carbon Fiber Microelectrode
Carbon fiber microelectrode (above) and the gold-plated amphenol (below) used
to connect the probe to the recording system head stage.

Figure 2.7 Schematic of a Carbon Fiber Microelectrode
The single channel recording tip of a carbon fiber microelectrode coated with
Nafion® (yellow)(left) to increase selectivity for DA, and an electromicrograph of a
carbon fiber microelectrode tip (Right).
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Figure 2.8 CMA/110 Liquid Switch
The CMA/110 Liquid Switch with 3 syringe capacity, blue tubing adapters, and
tubing (left) and the reverse side (right) with central outlet tube that connects to
the microdialysis probe.

Figure 2.9 CMA/11 Microdialysis Probe (2 mm membrane)
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Figure 2.10 Microsyringe Pump and1000µl Hamilton Syringes Containing
aCSF and Stimulant

Figure 2.11 ESA Coulochem III High Performance Liquid Chromatography
Electrochemical Detector and Auto-Sampler
Copyright © Barry Matthew Joyce 2006
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Chapter 3: Differential Effects of Amphetamine Isomers on Dopamine
Release in the Rat Striatum and Nucleus Accumbens Core
Introduction
Since their initial discovery in the mid 1900s, stimulants have been used
as first-line agents in treating ADHD.

Recently, development of sustained-

release delivery systems, racemic compounds, and single-isomers of already
approved stimulants have led to an increase in the number of marketed
stimulants available for treatment options. In the 1990s Adderall® was marketed
as a stimulant with an increased half-life of efficacy that attained approximately
29% of the market share in stimulant prescriptions by 2000 (Goodman and
Nachman 2000). The drug Adderall® is made of an equal-weight composition of
four

amphetamine

salts

(D-amphetamine

saccharate,

D,L-amphetamine

aspartate, D-amphetamine sulfate and D,L-amphetamine sulfate) yielding a
combination of 75% D-amphetamine and 25% L-amphetamine.

The longer

efficacy of Adderall® has generally been attributed to differential absorption of
component salts (Hampshire, Chineham, England), however, data supporting
this has never been shown. James et al. (2001) recently published the first
randomized, double-blind, cross-over comparison of Adderall® versus immediate
and timed-release D-amphetamine. This study demonstrated the faster onset
and longer duration of action of Adderall® when compared to D-amphetamine on
target symptoms of hyperactivity, however potencies between the two are similar.
Benzedrine® (D,L-amphetamine) had been used as a treatment for ADHD until
removed from the market in the 1970s due to the increased abuse potential
associated with this medication. A clinical study completed around this same
time indicated that individuals respond differently in regards to efficacy and side
effects of Benzedrine® versus D-amphetamine (Gross, 1976).
For several decades, stimulants such as methylphenidate and Damphetamine have been instrumental in treating the symptoms of ADHD and are
thought to be safe and effective. Given their widespread use, their mechanisms
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of therapeutic action in the context of ADHD remain unclear (Solanto et al. 2001;
Goodman et al. 2001).

In the presence of D-amphetamine, dose-dependent

increases in pre-synaptic dopamine (DA) and norepinephrine (NE) release occur
via a calcium-independent mechanism (Carboni et al. 1989; Kahlig and Galli
2003). Amphetamine is likely to be active at multiple cellular targets including the
vesicular monoamine transporter (VMAT), the DA transporter (DAT), and
monoamine oxidase (MAO).

The therapeutic nature of stimulants and their

known interactions with DA support the current consensus hypothesis that ADHD
symptomatology

is

neurotransmission.

likely

due

to

dysregulation

of

catecholaminergic

Interruptions in dopaminergic neurotransmission in the

prefrontal cortex, striatum, and nucleus accumbens have been implicated
(Solanto et al. 2001; Biederman and Faraone 2002).
In regards to increasing extracellular DA in the brain, L-amphetamine is
often considered to be inactive (Goodman et al. 2001) while differential
pharmacokinetic
amphetamine.

properties

have

been

shown

in

comparison

with

D-

L-amphetamine has displayed paradoxical effects such as

decreased locomotion in mice at low doses and increased locomotion in mice at
high doses (Stromberg and Svensson 1975).

Rats will self-administer L-

amphetamine, and children with ADHD have been successfully treated with Lamphetamine (Yokel and Pickens 1973; Arnold et al. 1976). Hippocampal data
have shown that the enantiomers initiate differential release of DA (Kuczenski et
al. 1995). Kanbayashi et al. (2000) showed that D-amphetamine treats different
symptoms than L-amphetamine in a canine model of narcolepsy.

D-and L-

amphetamine administered alone versus in combination and the relevance of the
enantiomer interactions have not been shown in the context of therapeutic doses.
For the studies described in this chapter we investigated the potential
differences between the dynamics of DA release produced by racemic
amphetamine (D,L-amphetamine) compared to D-amphetamine. In addition, we
directly compared the effects of the single D- and L-amphetamine enantiomers.
We tested the hypothesis that L-amphetamine has differential effects on DAT
regulation in comparison to D-amphetamine. We used the technique of high
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speed chronoamperometry coupled with Nafion®-coated single carbon-fiber
microelectrodes to measure locally-applied (D,L-, D-, and L-) amphetamineevoked DA release on a second-by-second basis in the striatum and nucleus
accumbens core of anesthetized Fischer 344 (F344) rats. Local applications of
drugs were used to avoid pharmacokinetic issues and interference with the
kinetics of the direct actions of amphetamine isomers.
Methods
Drug Concentrations used for In Vivo Electrochemical Recordings
The volume of applied drug was kept constant at 500 nl and was
measured using a dissection microscope fitted with a calibrated reticule (1 mm
change=25 nl of fluid) (Cass et al. 1992, 1993a; Friedemann and Gerhardt 1992).
Drugs were dissolved in 0.9% physiological saline and final drug solutions were
brought to a pH of 7.4. The amounts of drugs applied were determined as: 2
nanomoles D-amphetamine, 4 nanomoles D,L-amphetamine, 2 nanomoles D,Lamphetamine

and

2

nanomoles

L-amphetamine.

For

additional

methodological details, see Chapter 2.
Results
Amphetamine-Induced Release of DA
All amphetamine solutions applied locally yielded increases in extracellular
levels of DA and elongated signals similar to the slow releasing properties
associated with amphetamine and in comparison to the faster signals produced
via potassium induced depolarization release of DA (Hoffman and Gerhardt
1999).

Figure 2.1 (Chapter 2) displays the oxidation and reduction current

signals recorded following local application of approximately 500 nl of an
amphetamine solution. Carbon fiber microelectrodes that primarily measure DA
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were used according to in vitro calibration data; the average in vitro redox ratios
are shown as the inset of Figure 2.1. These ratios were compared to those
observed in vivo during the recordings in rat brain and indicated no significant
difference. However, these ratios were significantly different than in vitro redox
ratio measurements of 5-HT and the interferent ascorbic acid.
temperature

treated,

Nafion®-coated

microelectrodes

reliably

These highmeasured

amphetamine evoked DA signals that yielded the chemical fingerprint redox ratio
for DA (~0.78) (Gerhardt and Hoffman 2001).
Comparisons of D-amphetamine and D,L-amphetamine-Induced DA
Release in the Rat Striatum
At

equivalent

concentration

and

volume,

D-amphetamine,

D,L-

amphetamine and 2x D,L-amphetamine (double the concentration of the D,Lamphetamine to match the concentration of D-amphetamine used in the first
solution) were locally applied to the striatum.

A total of 28, 34, and 40 DA

release recordings for D-amphetamine, D,L-amphetamine and 2x D,Lamphetamine respectively were recorded.

Figure 3.1 displays representative

signals from 2 x D,L- and D-amphetamine-evoked DA, indicating the similar
amplitudes and significantly different time course of DA release signals: the inset
displays the differences in time course. When considering the amplitudes of the
recorded DA signals from multiple sites in the rat striatum, D,L-amphetamine
evoked significantly lower DA amplitudes that were approximately one-half of
those evoked by both D-amphetamine and 2x D,L-amphetamine (p<0.01, Fig. 3.2
a).

Amplitudes of the DA signals produced by D-amphetamine and 2x D,L-

amphetamine were not significantly different. In Figure 3.2 b the data were
expressed by the amplitudes of the DA signals in respect to the nanomoles of the
D-amphetamine isomer that was locally applied. In this format, the DA release
amplitudes were normalized and there was no significant difference between the
three amphetamine solutions. The amplitude of the DA signal was related to the
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concentration of the D-amphetamine isomer in the applied solution, and the Lamphetamine had little or no effect on the absolute amplitude of DA release.
The temporal properties of the evoked DA release signals were
significantly different between the D,L-amphetamine and D-amphetamine
solutions.

Rise time (TR) comparisons indicated that both D,L-amphetamine

solutions resulted in DA signals with significantly faster TR than D-amphetamine
(2 x D,L-amphetamine p<0.01; D,L-amphetamine p<0.05, Fig. 3.3 a). Finally,
D,L-amphetamine solutions yielded DA signals with a significantly faster T80
(p<0.001, Fig. 3.3 b).
Comparisons of D-, D,L-, and 2 x D,L-amphetamine- Evoked DA Release in
the Nucleus Accumbens Core
These studies were carried out to examine the effects of local applications
of D-amphetamine and D,L-amphetamine on DA release signals in the nucleus
accumbens core. A total of 17, 16, and 21 DA release signals, collected from
seven rats for each group, were used to make comparisons between Damphetamine,

D,L-amphetamine,

and

2x

D,L-amphetamine

respectively.

Amplitudes of DA release signals caused by D,L-amphetamine were significantly
lower than D-amphetamine and 2 x D,L-amphetamine-evoked DA release signal
amplitudes, while the latter two were not significantly different from each other
(p<0.05; Fig. 3.4 a). Figure 3.4 b shows the amplitude data normalized to the
nanomoles of the D-amphetamine isomer applied. Similar to data collected in
the striatum, there were no differences when viewing the amplitudes of DA
release in respect to the amount of D-amphetamine applied. These data support
that the overall DA release corresponded to the amount of D-amphetamine
isomer applied and was independent of the amount of L-amphetamine.
DA signal kinetic differences resulted in the nucleus accumbens core
analogous to data collected in the striatum.

D,L-amphetamine solutions

produced DA signals with faster TR than D-amphetamine-evoked DA release
(p<0.01; Fig 3.5 a). While T80 decay times were not significantly different when
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compared via repeated-measures ANOVA, significance was shown using a pair
wise comparison followed by Bonferroni corrections for multiple comparisons.
T80 decay times were significantly faster with D,L-amphetamine evoked DA
signals (p<0.001; Fig 3.5 b).
D-amphetamine Versus L-amphetamine Induced DA Release in the Striatum
and Nucleus Accumbens Core
A comparison of the properties of single isomer drug solutions were
carried out to investigate the effects of locally applied D-amphetamine and Lamphetamine on DA release in the striatum and nucleus accumbens core. A
major finding supported by these data was that D-amphetamine evoked DA
signal amplitudes were not significantly different from L-amphetamine evoked DA
signal amplitudes (Fig 3.6 a). DA release signals were recorded from a total of 9
rats, 34 signals for D-amphetamine and 7 rats, 17 signals for L-amphetamine.
Significantly faster TR and T80 were observed in the presence of L-amphetamine
when compared to D-amphetamine (p<0.001; Fig 3.6 b,c) similar to the
differences found between D-amphetamine and D,L-amphetamine. Similar to the
differences between D- versus L- amphetamine in the striatum, differences in the
nucleus accumbens were supported by data from a total of 4 rats with Lamphetamine and 16 rats with D-amphetamine (data not shown).
Discussion
The studies described here explain the faster onset and offset of DA
release in the presence of D-amphetamine versus D,L-amphetamine when the
drugs were applied locally to the striatum and core of the nucleus accumbens of
anesthetized rats. The amplitudes of DA release were related to the amount of
D-amphetamine present in the solution, and the presence of L-amphetamine only
seems to regulate the time course of DA release.

When comparing local

applications of the D- and L-isomers, we saw that the overall DA signal
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amplitudes were slightly smaller in the presence of L-amphetamine indicating its
potency in causing DA release in the CNS.

These findings are similar to

previous literature that support differential potency and efficacy reported in
clinical studies (Arnold et al. 1976). Comparatively, previous animal studies have
shown differences in the effects on behavior between D- and L-amphetamine
(Yokel and Pickens 1973; Jones et al. 1974; Smith and Davis 1977). In HEK 293
cells transfected with the human DAT (hDAT), L-amphetamine has been shown
to serve as a potential substrate for the transporter (Sitte et al. 1998). In regards
to measurements of transporter currents, the potency associated with Lamphetamine was three to six times lower than that reported with Damphetamine, while both D- and L- amphetamine produced similar currents.
This is the first time that the high temporal resolution of voltammetry has been
used to examine in vivo differences in the presence of rapid, first-time exposure
to stimulants as opposed to alternate systemic routes of administration. The data
presented in this chapter differ from data collected supporting greater differences
in potency between the amphetamine isomers and a lack of kinetic differences
that have been supported by data from alternative methodologies (Kuczenski et
al. 1995; Kanbayashi et al. 2000).
For these studies, L-amphetamine was given in combination with Damphetamine and the results support a theoretical mechanism describing the
role of L-amphetamine in altering D-amphetamine-evoked DA release.
possibility

involves

effects

interactions with the DAT.

not

previously

described

of

One

L-amphetamine

DA neurotransmission is rapidly regulated by the

DAT, and a plausible explanation is a novel relationship between the DAT and Lamphetamine (Gulley and Zahniser 2003).

On the order of seconds (acute

amphetamine exposure), previous information support the down regulation of
DAT activity in two ways:

by direct inhibition of D-amphetamine or via the

internalization of the DAT from the membrane to intracellular locations regulated
by protein kinase C. L-amphetamine could block the rapid down regulation of
membrane DAT activity caused by D-amphetamine. This would allow the rapid
efflux of DA through the DAT and a faster influx of DA via DAT reuptake after the
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DA signal amplitude approaches its peak measurement.

Potential L-

amphetamine competitive inhibition may block D-amphetamine for the D2R
autoreceptors that would phosphorylate the DAT downstream via PKC.

A

second explanation could involve a target site on the DAT where L-amphetamine
may inhibit rapid down regulation caused by D-amphetamine. This hypothesis
could be studied in cells transfected with the hDAT, while measuring the Vmax of
D-amphetamine evoked DA efflux with or without L-amphetamine. The study of
second messenger regulation involved in this process would be valuable for
determining its role in DAT membrane expression and/or activity. While these
are potential mechanisms of activity, it is possible that these differential effects
are being determined via other cellular targets such as MAO inhibition, V-MAT
effects, or direct regulation of the DAT and/or DA receptors.
These studies were designed to measure the effects of amphetamines
used for the treatment of ADHD on DA neurotransmission however some
caveats should be noted. While a racemic mixture of D- and L-amphetamine
was used and compared to D-amphetamine, this combination of amphetamine is
not commercially available except in the form of Adderall®, 25% L-amphetamine:
75% D-amphetamine.

In Chapters 4 and 5, we present data describing the

effects of Adderall similar to what is commercially available. Therapeutic levels
of amphetamine are projected to be in the range of 10-50 µM (Shader er al.
1999; Solanto et al. 2001) or even lower, however, the concentrations used for
these studies may have been higher. Concentrations were used that would have
yielded effective tissue concentrations in the range of 40-400 µM based on local
dilution of the applied drug after ejection from the micropipette (Gerhardt and
Palmer 1987). Data collected at lower drug concentrations will be presented in
Chapters 4 and 5. The F344 rats that were used for analysis are not animal
models of ADHD; therefore the information gained from these studies explain the
normal biology of the system and not a diseased model.

The recordings

completed for this study were taken from the striatum and nucleus accumbens
core of rats allowing for predominant measurement of DA versus other
neurotransmitters that may be important to the effects of amphetamine on the
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CNS. The drug solutions were locally applied to the brain region of interest
circumventing issues of systemic nature that would be caused by oral or
intraperitoneal dosing of amphetamine (Gerasimov et al. 2000). It is necessary
to carry out future studies that will use lower doses/concentrations of stimulant
medications to mimic the therapeutic effects (Kuczenski and Segal 2001).
The data support that D,L-amphetamine and L-amphetamine locally
applied to the striatum and nucleus accumbens result in more rapid release of
DA in comparison to evoked DA release caused by D-amphetamine. The data
shown here indicates that L-amphetamine does not significantly increase DA
release evoked by D,L-amphetamine, yet it evokes a similar DA response when
applied alone.

In correlation with clinical and experiment data, our findings

suggest that the presence of L-amphetamine given alone, or in combination with
D-amphetamine can cause differential behavioral effects relative to Damphetamine. Future studies are needed to create a better explanation of the
mechanisms of drugs that are used in the treatment of ADHD.
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Figure 3.1 Representative DA Release Signals Evoked by D- and 2 x D,Lamphetamine
Representative DA release signals from the F344 rat striatum indicating the time
course of DA release. The faster TR and T80 of 2x D,L-amphetamine is indicated
by the solid line and the longer time kinetics of D-amphetamine is shown by the
dashed line.

Inset:

The first minute of DA release of these representative

signals and their significant differences.
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Figure 3.2 Amplitudes of Amphetamine-Evoked DA Signals in the Striatum
a. Amplitudes of DA release recorded in the striatum following local application of
D-amphetamine, D,L-amphetamine, and 2 x D,L-amphetamine.

2 x D,L-, D-

amphetamine versus D,L -amphetamine (**p<0.01). b. Amplitudes of DA release
normalized with respect to nanomoles D-amphetamine in the drug solution.
Redox ratios of predominantly DA confirmed signal identities.
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Figure 3.3 Kinetics of Amphetamine-Evoked DA Release Signals in the
Striatum
a. Rise times of DA release signals evoked by local applications of
amphetamine in the rat striatum. D,L-amphetamine and 2x D,L-amphetamine
versus D-amphetamine; *p<0.05 and **p<0.01, respectively.

Redox ratios of

predominantly DA confirmed signal identities. b. T80 decay times of DA release
signals evoked by local applications of amphetamine in the rat striatum. D,Lamphetamine and 2x D,L-amphetamine versus D-amphetamine; ***p<0.001.
Redox ratios of predominantly DA confirmed signal identities.
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Figure 3.4 Amplitudes of Amphetamine-Evoked DA Signals in the Nucleus
Accumbens Core
a. Amplitudes of DA release recorded in the nucleus accumbens core following
local

application

amphetamine.

of

D-amphetamine,

D,L-amphetamine,

and

2

x

D,L-

D,L-amphetamine versus D-amphetamine (*p<0.05).

b.

Amplitudes of DA release normalized with respect to nanomoles D-amphetamine
in the drug solution.

Redox ratios of predominantly DA confirmed signal

identities.
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Figure 3.5 Kinetics of Amphetamine-Evoked DA Release Signals in the
Nucleus Accumbens Core
a. Rise times were significantly longer for D-amphetamine versus D,L-, and 2 x
D,L- amphetamine (**p<0.01) b. T80 decay times were significantly longer for Damphetamine versus D,L-, and 2 x D,L- amphetamine (***p<0.001).
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Figure 3.6 Amplitude and Kinetics of D- and L-amphetamine Evoked DA
Release in the Striatum (Continued on next page)
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Figure 3.6 Continued a. DA release signal amplitudes comparing the effects of
single enantiomer applications of D- and L-amphetamine in the striatum revealed
no significant differences. b. L-amphetamine rise times were significantly faster
than D-amphetamine rise times (***p<0.001). c. T80 decay times of Lamphetamine were significantly faster than D-amphetamine (***p<0.001).
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Chapter 4: Adderall® Produces Increased Striatal Dopamine Release and A
Prolonged Time Course Compared to Amphetamine Isomers
Introduction
Adderall® has been available for clinical use since the 1990s and was
initially advertised as a long-acting amphetamine that would eliminate the need
for multiple administrations during the day (Popper 1994). The drug made a
prominent entry into the market and by the turn of the century constituted 25% of
the prescriptions written for ADHD (Goodman and Nachman 2000). Recent data
indicate that Adderall® in its extended release form (Adderall XR®) continues to
increase in yearly sales that now outsell the main methylphenidate sustained
release form, Concerta® (Mathews 2006). Adderall® consists of a combination of
four amphetamine salts:

D-amphetamine saccharate, D,L-amphetamine

aspartate, D-amphetamine sulfate, and D,L-amphetamine sulfate at equal
weights.

This mixture gives an approximate amount of D- versus L-

amphetamine of 75-80% and 20-25% in a 10 mg tablet (Patrick and Markowitz
1997).
The prolonged activity of this drug in its immediate release form has been
suggested by the pharmaceutical company (Hampshire, Chineham, England) to
be due to the differential absorption of the component salts, however these data
were never published (Popper 1994). The first randomized, double-blind,
crossover comparison of Adderall® versus D-amphetamine supports that
Adderall® worked slightly faster and lasted longer than D-amphetamine (at the
same total doses) in decreasing hyperactivity, while the two drugs displayed
similar potencies (James et al. 2001). There are few published studies reporting
the in vivo DA releasing properties of clinically used stimulants such as Adderall®
and Dexedrine® (100% D-amphetamine).
D-amphetamine and related isomers are believed to promote presynaptic
release of dopamine (DA) in the striatum by inducing reverse transport and
blocking the reuptake capabilities of the dopamine transporter (DAT) (Glowinski
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et al. 1966; Carboni et al. 1989; Sulzer et al. 1993, 1995; Pierce and Kalivas
1997; Gnegy et al. 2004). The apparent interaction between amphetamine and
DA/NE neurotransmission supports the current consensus hypothesis that ADHD
symptomatology results from dysregulation of the release properties of
catecholaminergic projections to the prefrontal cortex and/or striatum (Solanto et
al. 2001; Biederman et al. 2002). The data support differences between the
pharmacokinetic properties of D-amphetamine and L-amphetamine.

L-

amphetamine is noted to be slightly more potent than D-amphetamine in use as
a sympathomimetic drug while the D-isomer is suggested to be 3 to 4 times more
potent than the L-isomer in acting as a central nervous system stimulant
(Goodman et al. 2001). Rats are known to self administer L-amphetamine and
data support that it is effective in treating children with ADHD (Arnold et al. 1972,
1976; Yokel and Pickens 1973,1974).
In this study, we investigated clinical reports of differential response to
Adderall® by comparing the dynamics of DA release evoked by D-amphetamine,
D,L-amphetamine, and Adderall® in the striatum of anesthetized rats. Our prior
studies support that there are differences in kinetics of evoked DA release that
differ between D-amphetamine and D,L- amphetamine when locally-applied in rat
striatum (Chapter 3).

High speed chronoamperometry coupled with Nafion®-

coated single carbon fiber microelectrodes was used to test the hypothesis that
the enantiomers and/or components of Adderall® evoke greater DA release in rat
striatum with a longer time course. This is the first in vivo demonstration of the
effects of Adderall® versus D-amphetamine and D,L-amphetamine on DA
neurotransmission using local applications of drugs to evaluate their effects in the
rat brain. Drugs were applied in low levels to better simulate clinically relevant
levels of these ADHD medications, and locally to eliminate drug pharmacokinetic
issues from the study.

The success of stimulant treatments for ADHD to

decrease hyperactivity and increase attention is known to be highly variable from
one patient to another (Rapoport et al. 1978; Elia et al. 1991). Since the primary
purpose of these studies was to assess mechanistic properties using low levels
of amphetamine, we chose normal, developmentally mature adult (3-6 month
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old), F344 rats to study the effects of amphetamine isomers on striatal DA
neurotransmission.
Methods
Drug Concentrations used for In Vivo Electrochemical Recordings
The volume of applied drug was kept constant at 500 nl and was
measured using a dissection microscope fitted with a calibrated reticule (1 mm
change=25 nl of fluid) (Cass et al. 1992, 1993a; Friedemann and Gerhardt 1992).
Drugs were dissolved in 0.9% physiological saline and final drug solutions were
brought to a pH of 7.4. Adderall®, D,L-amphetamine or D-amphtamine solutions
were applied in the following amounts (0.68 nanomoles Adderall®, 1 nanomole
D,L-amphetamine, and 0.5 nanomoles D-amhetamine). Therefore a constant 0.5
nanomoles of the D-amphetamine isomer were applied in all drug treatments in
Chapter 4 in order to investigate the effects of differing amounts of Lamphetamine. For methodological details, see Chapter 2.
Results
Signal Confirmation
After local applications of the amphetamine solutions to the striatum, the
resulting DA signals exhibited slow release and uptake properties as compared
to the faster properties of DA signals produced by depolarization with potassium
applications (Friedmann and Gerhardt 1992).

We confirmed that our

microelectrodes were measuring primarily DA by comparing the mean redox
ratios obtained in vivo to those of in vitro calibrations, finding no significant
differences similar to data shown in Figure 2.1 of Chapter 2. However, our redox
ratios were significantly different from the much lower ratios obtained from in vitro
measures of serotonin (5-HT) and ascorbic acid (Fig. 2.1). Taken together, our
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measurements confirm that Nafion®-coated carbon fiber microelectrodes used for
these studies were capable of measuring signals that match the chemical
fingerprint for DA upon local applications of amphetamine solutions and that
signals produced by locally-applied D-amphetamine were predominantly DA.
Comparisons of Adderall®, D-amphetamine, and D,L- amphetamine in the
Rat Striatum
These studies investigated the effects of locally applied amphetamine
solutions of D,L-amphetamine, Adderall®, and D-amphetamine. Significant
differences were found among the resulting DA signal amplitudes. Figure 4.1
shows three representative DA release signals from applications of Damphetamine, D,L-amphetamine, and Adderall® and the differences in
amplitudes and time courses of the signals.

The respective in vivo redox ratios

(0.7-0.8) of the three drug-induced signals, indicative of predominantly DA
release signals, are shown in the inset of Figure 4.1.
Applications of Adderall® resulted in significantly greater DA release
amplitudes compared to D-amphetamine (p<0.001) and D,L- amphetamine
(p<0.001) supportive of a greater effect on DA neurotransmission (Fig 4.2 a).
Adderall® showed nearly a 40% greater effect on DA release amplitude in
comparison to the other amphetamine isomers, providing the first in vivo data in
parallel with the noted clinical efficacy of this drug. The amplitude of DA released
per nanoliter of drug applied was significantly greater for Adderall® than for the
other drugs tested indicating greater effects on evoked DA release at the same
volume of drug applied into rat striatum (Fig. 4.2 b; p<0.001). This effect was
achieved with the same number of equivalents of D-amphetamine in the
Adderall® drug solution. This information supports the increased magnitude of
DA evoked by D-amphetamine in the context of a smaller amount of Lamphetamine.
Temporal differences in the drug-evoked signals were also observed in
the rise times (TR) and 80% decay times (T80) among Adderall®, D,L-
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amphetamine, and D-amphetamine (Fig. 4.3 a, 4.3 b; p<0.001, p<0.05).
Adderall®, as shown in Figure 4.3 a, evoked DA release over a significantly
longer period of time as compared to the other drugs supporting the increased
time course of activity associated with this drug in the clinic (p<0.001).

D-

amphetamine evoked DA release over a small but significantly longer time period
in comparison to D,L-amphetamine, replicating our work described in Chapter 3
(Fig. 4.3 a; p<0.05). The 40% longer effect on TR by Adderall® greatly contributes
to the increased amplitude and total area of Adderall®-evoked DA signals. Figure
4.3 b shows the significant differences in decay times among Adderall®, Damphetamine, and D,L-amphetamine (p<0.001) indicative of an increased effect
on the time course of DA release.

The 50% longer T80 associated with the

clearance of Adderall®-evoked DA release is likely due to a greater amount of DA
that remains to be cleared.

This likely has implications on the clearance

capacity/availability of the DAT that is available to remove DA from the
extracellular space (Cass et al. 1993b; Giros et al. 1996; Saunders et al. 2000;
Gulley et al. 2002; Madras et al. 2002; Kahlig and Galli 2003; Kahlig et al. 2004).
The increased T80 associated with Adderall® theoretically supports that the
components of Adderall® cause an initial DAT upregulation to the plasma
membrane or changes DAT conformation to allow more DA to pass through.
This is followed by a very potent blockade and/or a decrease in plasma
membrane or functional DAT levels that contribute to the elongated Adderall®
evoked DA release signals.
Discussion
In summary, these are the first in vivo data reporting differences between
Adderall®, D-amphetamine, and D,L-amphetamine and their effects on DA
release signal properties in rat striatum with potential implications to their clinical
differences. Adderall® produced DA release signals with the longest rise time
and decay time as compared to D-amphetamine and D,L-amphetamine.
Differences were also observed between the effects of D- and D,L-amphetamine
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on the kinetics of DA release. Taken together, these data support the hypothesis
that Adderall® evokes greater DA release in rat striatum with a longer time
course, which is produced by the combination of amphetamine enantiomers
and/or salts present in the drug solution.
While these studies were designed to investigate the effects of
amphetamine isomers on DA release and uptake properties, the clinical
implications of these data should be interpreted with caution.

Acute local

applications of stimulants in anesthetized animals do not mimic repeated
systemic administration of stimulants in ADHD patients. Route and time course
of amphetamine administration have been shown to affect DA measures in
microdialysis studies (Kametani et al. 1995; Purdom et al. 2003) supporting the
use of drug-naïve animals for these studies. Although it would be most ideal to
apply the stimulants in amounts that mimic the level striatal nerve endings would
see physiologically with administration of oral medication for ADHD, data on what
these concentrations may actually be, and the comparative dosing levels for a rat
compared to the human are not exactly known. Therefore we chose to apply the
stimulants at a concentration designed to both give us consistent and
comparable DA responses, as well as be at an intermediate portion of the Damphetamine concentration-response curve.

Further data on the stimulant

concentration-response curves are shown in Chapter 5.
These data are consistent with previous reports that this drug has been
designed to work over a longer time scale, including its initial effects on DA
release and its overall activity half-life (Cody et al. 2003). In addition, these data
correlate with clinical reports of increased duration of action of Adderall® when
compared to D-amphetamine in regards to measures of locomotor activity in
humans (James et al. 2001).

These findings replicate our previous in vivo

voltammetric studies that investigated differences between D-amphetamine and
D,L-amphetamine evoked DA release signals (Chapter 3). In Chapter 3, we
concluded that local applications of D,L-amphetamine caused a faster release of
DA than D-amphetamine alone in the striatum and nucleus accumbens core.
Our present study showed similarities to our previous data in respect to DA
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release signal amplitudes as well as significant differences in the rise time of the
signals between D- and D,L-amphetamine.
The current study points to differential interactions between these
stimulant drugs and the DAT. The Adderall® data support that it regulates the
DAT in such a way that it remains capable of reverse transport of DA into the
extracellular space and then blocks the uptake of DA both over a longer time
period (Fig. 4.4). It is also important to note that nearly all of the DA signals
recorded in the presence of Adderall® were prolonged and signal decay was
typically longer than 5 minutes, almost double the signal decay times of the other
drugs tested. The kinetic differences observed indicated an overall elongated
Adderall® effect on DA release similar to previous DA uptake studies carried out
in the rat striatum after exposure to a selective DA uptake inhibitor, GBR- 12909
(Cass and Gerhardt 1995). The amplitude of DA released per volume of drug
applied was highest with Adderall®, indicating a greater evoked DA response
elicited than if the same volumes of D-amphetamine and D,L-amphetamine were
locally administered. While the current data provide evidence for amphetamine
salt and/or isomer dependent differences in DA evoked release, additional
studies are necessary to examine specific component interactions with the DAT.
Due to the elongated time course of the Adderall®-evoked DA release
signals, we suggest that Adderall® may be causing reverse transport of DA
through the DAT over a longer time period. However, a consideration of recent
literature describing DAT-substrate effects poses other theoretical explanations.
The DAT is a dynamic protein that shuttles to and from the plasma membrane or
can undergo conformational changes to regulate its ability to transport DA in and
out of the cell (Kahlig et al. 2004; Johnson et al. 2005). Johnson et al. (2005)
performed in vitro synaptosome studies to assess substrate dependent changes
in DAT function and found that plasma membrane availability of DATs increased
in response to acute exposure of amphetamine (<1 min), however the available
DATs differed in their capacity to transport DA.
While these studies provide acute exposure of drug over 30 seconds,
similar to the 20 second application time for our studies, there was an increase in
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DAT plasma membrane availability over this time frame.

Previous work

investigating hDAT transfected HEK 293 cells has indicated that both
enantiomers of amphetamine are substrates with differing potencies and similar
transporter currents (Sitte et al. 1998). Likewise, in vitro data support differential
DAT states that determine the rate and amount of DA that can pass in response
to amphetamine (Kahlig et al. 2005).

Kahlig et al. (2005) described two

independent mechanisms by which DAT-mediated DA efflux can occur: a highly
regulated facilitated exchange mechanism or a more rapid process that allows for
bursts of DA efflux through an open channel.
Considering the noted in vitro observations of the DAT, we propose Lamphetamine in Adderall® may be altering DAT function or availability to regulate
the efficiency by which DA is allowed to pass through. Upon initial application of
Adderall®, 1) externalization of the DAT may occur (Johnson et al. 2005) similar
to initial cocaine induced upregulation of the DAT to the plasma membrane
(Zahniser and Sorkin 2004) or 2) DATs may undergo conformation changes to an
open channel mode (Kahlig et al. 2005) to allow large amounts of DA to exit the
cell representing the large amplitudes seen in our DA release signals.
Secondary modifications of plasma membrane DAT function or availability
(trafficking) could decrease plasma membrane levels of DATs similar to DAT
levels after chronic cocaine exposure (Gulley et al. 2002; Zahniser and Sorkin
2004). The decreased plasma membrane availability of the DAT would lead to
accumulation of extracellular DA over a longer time period to explain the
elongated Adderall®-evoked DA release signals. This could be accomplished via
DA receptor and PKC dependent protein-protein interactions that regulate DAT
conformation and functional states (Fig. 4.4) (Torres et al. 2003; Khoshbouei et
al. 2004).
In summary, we have shown that Adderall® has a greater effect on DA
release in the rat striatum compared to D- and D,L- amphetamine. This study
documents important information concerning low levels of ADHD drugs and the
differences seen in evoked DA release signals when varying the ratio of Damphetamine to L-amphetamine and salt components.
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These findings are

similar to clinical data suggesting that Adderall® may be a more potent or a
longer acting drug choice for certain behavioral symptoms of ADHD.

Future

studies are needed to elucidate the specific mechanisms governing Damphetamine and Adderall®-induced release of DA in vivo.

68

Figure 4.1 Representative DA Release Signals Caused by Local
Applications of Adderall®, D-amphetamine, and D,L-amphetamine in the
Striatum
Typical recordings indicating the time course of DA release in the striatum of rat
brain induced by D,L-amphetamine (circles), D-amphetamine (triangles), and
Adderall® (squares). All drug solutions contain an equivalent 0.5 nmol of Damphetamine. Inset: Measured average in vivo redox ratios of all DA release
signals, indicative of predominantly DA, included for statistical analysis (n=30, 42,
54 signals; error bars represent S.E.M).
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Figure 4.2 Amplitudes of DA Release Signals in the Striatum After Local
Applications of Adderall®, D,L-amphetamine, and D-amphetamine
a. The amplitudes of DA release measured in the rat striatum after local
application of Adderall® were significantly greater compared to D-amphetamine,
or D,L-amphetamine (***p<0.001). b. Amplitude of DA (nM) recorded per volume
of drug applied (nl) in the rat striatum was significantly greater for Adderall® in
comparison to D-amphetamine and D,L-amphetamine (***p<0.001).

All drug

solutions contained an equivalent 0.5 nmol D-amphetamine. Data analyzed by
MANOVA with Tukeys post-hoc comparisons; error bars represent S.E.M.
(n=animals, signals; 10, 54; 10, 42; and 10, 30).
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Figure 4.3 Kinetics of DA Release Signals After Local Applications of
Adderall®, D,L-amphetamine, and D-amphetamine in the Striatum
a. Rise times for Adderall®-evoked DA release signals in the rat striatum were
significantly longer than D-amphetamine or D,L-amphetamine evoked DA signals
(***p<0.001). Rise times for D-amphetamine evoked DA release signals were
significantly longer than D,L-amphetamine evoked DA signals similar to prior
studies (†p<0.05). b. T80 decay times for Adderall®-evoked DA release signals in
the rat striatum were significantly longer than those produced by D-amphetamine
or D,L-amphetamine (***p<0.001).

Data analyzed by MANOVA with Tukeys

post-hoc comparisons; error bars represent S.E.M. (n=animals, signals; 10, 54;
10, 42; and 10, 30).

71

Figure 4.4 Theoretical Model of Activity Describing Adderall®
Evoked- DA Release Signals
A. Physiological Function of the DAT:

Under normal conditions, the DAT

functions to remove presynaptically released extracellular DA for recycling and
intracellular degradation (Cooper et al. 1996).

B. Phase I Adderall®:

Amphetamine is theorized to cause a reversal of DA transport through the DAT
while also blocking future DA reuptake (Seiden and Sabol 1993; Solanto et al.
2001).

Down regulation of DAT activity results via amphetamine blockade,

modulation of DAT function, or endocytosis of the DAT over a longer time period
for Adderall® (Gulley and Zahniser 2003; Torres et al. 2003; Kahlig and Galli
2003; Khoshbouei et al. 2004; Kahlig et al. 2005).

Early on, Adderall® may

potently induce an open-pore mode of the DAT or cause an upregulation of
plasma membrane DATs to allow increased levels of DA to pass through (Kahlig
et al. 2005; Johnson et al. 2005). C. Phase II Adderall®: Down regulation of
plasma membrane DATs or inhibition of DAT function supports the elongated
decay times seen with Adderall® (Saunders et al. 2000; Gulley et al. 2002;
Zahniser and Sorkin 2004; Kahlig et al. 2004).
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Chapter 5: Reverse Microdialysis Studies of the Effects of Psychomotor
Stimulants Used to Treat ADHD on Extracellular Dopamine
Introduction
Attention-deficit/hyperactivity

disorder

(ADHD)

has

an

estimated

prevalence of 3-17% in school age children with stimulant medications being
used as the predominant mode of treatment (Lahey et al. 1999; Goldman et al.
1998; Solanto et al. 2001). Cardinal symptoms of ADHD, such as impulsivity,
inattention, and motor restlessness, lead to impairment of function in social,
school, and home settings that are improved by treatment with stimulant
medications (DSM-IV-TR 2000).

In 2004, prescription sales of stimulants for

ADHD totaled $3.1 billion dollars, while 2.5 million children and 1.5 million adults
were estimated to use these medications (Vedantam 2006). Until 2005, sales of
methylphenidate exceeded the other treatment options.

However, while

collecting the data for these studies, sales of Adderall® ($1.16 billion) were
similar or surpassed sales of methylphenidate ($929 million) medications during
calendar year 2005 (Mathews 2006). At the current time, all ADHD medications
are under scrutiny from the media in light of FDA hearings regarding potential
risks and a need for further characterization.
Dexedrine® (D-amphetamine), Adderall® (mixed-salts amphetamine), and
Ritalin® (methylphenidate) are thought to reduce the symptoms of ADHD via
actions on dopamine (DA) and norepinephrine (NE) nerve endings in the CNS
(Solanto et al. 2001). However, their mechanisms of action on neurotransmitter
release and uptake remain speculative (Ohno 2003). Specifically, frontal cortex
and subcortical neural networks (including structures of the basal ganglia) are
implicated in MRI morphological studies of ADHD versus healthy controls
(Durston 2003; Solanto et al. 2001; and Sowell et al. 2003). Within these brain
structures, catecholaminergic membrane transporters are targets of most ADHD
stimulants; however, previous data support differential mechanistic theories at
the level of neurotransmission.

Stimulants inhibit the dopamine transporter
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(DAT) causing DA levels to increase (Bergman et al. 1989; Cadoni et al. 1995;
Wall et al. 1993).

While amphetamine is suspected to facilitate DA

neurotransmission, in general, it is uncertain what differences exist between the
optical isomers of amphetamine and how they compare to the effects of
methylphenidate. In the 1990s the drug Adderall®, containing a mixture of 7580% D- and 20-25% L-amphetamine across four component salts, was
introduced and marketed as a robust treatment for the symptoms of ADHD
compared to other medications (Popper 1994; Patrick et al. 1997). One clinical
study compared Adderall® to D-amphetamine and found that Adderall®
decreased specific symptoms of hyperactivity slightly faster and over a longer
time period than D-amphetamine (James et al. 2001).

Other clinical trials

support that Adderall® is more effective than methylphenidate on outcomes
measured 4 to 5 hours after dosing (Pelham et al. 1999). Adderall® given as a
single morning dose was equivalent to methylphenidate received twice daily in
regards to clinical improvements during the day (Pelham et al. 1999). In addition,
methylphenidate has been characterized to have similar effects on DATs as
cocaine. Sonders et al. (1997) categorized pharmacological agents that act on
the human dopamine transporter (hDAT) into two groups: DA-like (including DA
and amphetamine) and cocaine-like (including cocaine and methylphenidate).
Our previously published in vivo voltammetry data showed differences in
kinetics between amphetamine optical isomers (Chapter 3). For these studies,
we found that drugs with L-amphetamine produced faster rise times and signal
decay times compared to D-amphetamine. Additionally, data collected by our
group showed greater amplitudes and longer DA response signal kinetics
following local applications of Adderall® in comparison with D-amphetamine and
D,L-amphetamine (Chapter 4).

Our previous studies support differential

interactions with the mechanisms responsible for presynaptic DA release.
Due in part to the clinical reports of Adderall® efficacy in comparison to
other ADHD treatments, we set out to test the hypothesis that D-amphetamine
and Adderall® (75% D- 25% L- amphetamine) will differ in resulting extracellular
DA response over a range of concentrationss. In addition, we speculated that
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increased DA levels will be produced by amphetamine compared to little or no
DA response after local applications of methylphenidate and cocaine in
anesthetized rats. This concentration-response characterization was carried out
using reverse microdialysis in drug-naïve animals to circumvent issues regarding
DAT trafficking and/or change in function following substrate exposure (Kahlig
and Galli 2003; Kahlig et al. 2004; Purdom et al. 2003). Finally, we compared
these drugs with a novel combination of 25% D- 75% L- amphetamine and
termed this “Reverse Adderall” to investigate the efficacy and potency of a drug
with more L- than D-amphetamine.

We sought to construct concentration-

response curves for DA and 3,4 dihydroxyphenylacetic acid (DOPAC) of these
drug solutions to further describe the properties of stimulants that make use of
different combinations of amphetamine isomers. The concentration range
included clinically relevant and high-dose effective tissue concentrations
potentially relevant to stimulant abuse. Using the technique of microdialysis we
were able to take measures of DA metabolites following degradation by
monoamine oxidase. We suspected that differential effects on metabolite levels
would result. Studies of individual concentration-response curves of stimulant
drugs will demonstrate differential effects the drugs have on DA and metabolite
levels. In addition, these are the first experiments, to our knowledge, that have
investigated these drugs in the context of ADHD using a local administration
method.
While we have described the use of voltammetric studies to investigate
the properties of stimulants at low levels, it is difficult to accurately predict what
the resulting effective concentrations were. Voltammetry affords the ability to
study neurotransmission with high temporal and spatial resolution; however, we
lose a magnitude of sensitivity that is available using High Performance Liquid
Chromatography (HPLC) with electrochemical detection (EC). Using HPLC-EC
to analyze samples collected during reverse microdialysis (local application) of
stimulant drugs allows for studies to be carried out with more accurately
projected drug concentrations. These studies were designed to complement our
previous studies and mimic longer administration (over 20 minutes) in converse
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to the rapid pressure ejection used earlier (20 seconds). As a final rationale of
this work, we proposed to investigate complete concentration-response studies
using reverse microdialysis coupled with HPLC-EC.

Our data are the first

characterizations of these drugs across low (clinical) and high (abuse) levels
using local applications of stimulant drugs.

Investigations of concentration-

response patterns were intended to increase our understanding of ADHD drug
mechanistic activity by looking at their effects on DA and metabolite levels.
For methodological details, see Chapter 2.
Results
Basal Levels of DA and DOPAC
Measures of the analytes were consistent with previous data of samples
taken from the striatum. Average baseline levels of DA (<10 nM) were measured
and found to be similar to previously collected data in the striatum of
anesthetized and awake-behaving rats (Gerhardt and Maloney 1999; Ferguson
et al. 2003; Garris et al. 1994; Kawagoe et al. 1992; Parsons and Justice 1992)
(Fig. 5.1-5.4). Baseline DOPAC levels were determined to be (~800-1000 nM) in
the rats used for the D-amphetamine and Adderall® studies and were similar to
previously reported levels (Ferguson et al. 2003) and lower than other reports of
DOPAC measures that have been above 1000 nM.

The DOPAC data were

represented in percent of baseline due to increased variance in baseline samples
collected from the rats used for the Reverse Adderall and methylphenidate
studies (Fig. 5.5-5.8).

Homovanillic acid (HVA) levels were determined as

percent of baseline, and no additional analysis was completed due to similarities
between the data sets (Fig. 5.11).
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Comparisons of DA and Metabolite Response After Reverse Microdialysis
of Stimulants in the Striatum
The

twenty

minute

local

tissue

perfusions

of

drugs

(including

methylphenidate) induced a dose-dependent increase in DA overflow followed by
a 60 minute time period to return to baseline supporting the DAT and DA uptake
blocking effects of the tested stimulants (Fig. 5.1-5.4) (Wise and Hoffman 1992;
Sulzer et al. 1993; Castellanos et al. 1996; Schweri et al. 1985). The resulting
DA levels, at the highest concentration of drug, were similar to previous
microdialysis measures of ~150 nM (Seeman and Madras 2002). The measures
of DA were elongated over 40 minutes (2 samples) after stimulus compared to
local perfusions of potassium, which depolarizes the cell and causes subsequent
return of DA levels to baseline within 20 minutes (1 sample) after removal of
potassium solution (Hebert et al. 1996; Purdom et al. 2003; Stanford et al. 2001).
Furthermore, applications of low concentrations of stimulants did not result in DA
levels being higher than levels after artificial cerebral spinal fluid (aCSF) control
(Fig. 5.1-5.4).
The resulting D-amphetamine concentration-response curve of DA in rat
striatum displayed a double-sigmoidal pattern that supports biphasic effects on
DA stores and/or DAT trafficking (Fig 5.1) (Kahlig et al. 2005). Plateaus in the
DA response occurred at the lower concentration (1 µM D-amphetamine) and at
a higher concentration (100 µM D-amphetamine). At 0.1 µM D-amphetamine,
little or no increase in DA overflow resulted in comparison to aCSF control; and
no significant differences were found between 100 µM and 400 µM Damphetamine supporting an upper plateau in DA measures (Fig 5.1). While two
half-maximal effective concentration (EC50) values are indicated for the lower (Damphetamine I) and upper (D-amphetamine II) portions of this concentrationresponse curve (Table 5.1), the EC50 of D-amphetamine II was used to make
conclusions regarding potency and efficacy.
The resulting methylphenidate concentration-response curve of DA in the
rat striatum supports a dose-dependent increase in DA levels (Fig 5.2). Since
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methylphenidate had previously been characterized as a DAT blocker and not a
substrate that undergoes transport through the DAT, we hypothesized that we
would see little or no change in DA levels in an anesthetized rat. Applications of
0.5-400 µM methylphenidate increased DA concentrations significantly greater
than aCSF control. 0.1 µM methylphenidate did not cause increased DA levels
significantly different from control indicating the lower plateau of the
concentration-response curve. The two highest concentrations tested (100 and
400 µM) were not significantly different supporting an upper level plateau (Fig.
5.2).
Figure 5.3 displays the resulting Adderall® concentration-response curve
of DA measured in the rat striatum. An upper plateau in DA levels occurred at
100 µM Adderall, as 100 µM and 400 µM Adderall were not significantly different
in response. At 0.1 µM Adderall, DA levels were not significantly different from
local application of aCSF control.

Finally, the Reverse Adderall (75% L-

amphetamine, 25% D-amphetamine) concentration-response curve of DA
showed a dose-dependent increase in evoked DA at all concentrations tested
except for 0.1 µM; which was not significantly different from aCSF control (Fig.
5.4). While Reverse Adderall was predominantly made of L-amphetamine, it did
not increase DA levels to the extent of Adderall® at some concentrations (Table
5.1).

The highest two concentrations of Reverse Adderall tested were

significantly different supporting that a plateau of DA measures will likely occur at
a higher concentration.
Comparisons of Potencies of Stimulants after Reverse Microdialysis
in the Striatum
Potencies were extrapolated from the median concentration along the
concentration-response

curves

for

D-amphetamine

II,

methylphenidate,

Adderall®, and Reverse Adderall and are represented as EC50 in Table 5.1. The
stimulants in order of their potency on DA overflow were: methylphenidate (10
µM) > Adderall® (25 µM) > D-amphetamine II (50 µM) = Reverse Adderall (50
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µM). The two potency concentrations for D-amphetamine represent EC50 values
for both plateaus of the concentration-response curve of DA, however the most
similar response in effects on DA levels to the other stimulants tested is
represented in the above order of potency. The effects of methylphenidate on
increasing DA levels could be due to an action of methylphenidate only seen with
local application, but it is more likely that our anesthesia does not completely
remove spontaneous neuronal activity supporting that methylphenidate blocked
uptake of spike-dependent DA release (Sabeti et al. 2003; Kish et al. 1999).
These data support the increased potency of Adderall® and replicate data from
Chapter 4 that indicate that Adderall® had the greatest effect on DA release in
comparison to D- and D,L-amphetamine. Finally, Reverse Adderall (made of
predominantly L-amphetamine) and D-amphetamine were similar in potency
supporting the DA releasing properties of L-amphetamine and replicating the
data presented in Chapter 3 that DA signal amplitudes were similar between Dand L- amphetamine.
Comparisons of Efficacies of Stimulants after Reverse Microdialysis
in the Striatum
At the highest effective concentrations, Adderall® and Reverse Adderall
were similar in their effects on DA levels and caused greater increases in DA
levels than D-amphetamine and methylphenidate.
regards

to

increased

DA

methylphenidate were similar.

levels

resulting

Measures of efficacy in

from

D-amphetamine

and

In a comparison of these stimulants versus

cocaine, Adderall® (p<0.001) and D-amphetamine (p<0.05) caused significantly
greater increases in DA levels than cocaine (Fig. 5.9 a). While these data did not
support that methylphenidate caused significantly greater DA levels compared to
cocaine, average DA increases resembled that caused by amphetamine isomers
more so than cocaine (Fig. 5.9a).

These data support an unpredicted

dissociation of methylphenidate and cocaine, likely visible due to the local
application of drugs used in these studies. Reverse Adderall (p<0.01) and L-
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amphetamine (p<0.05) caused significantly greater DA levels when compared to
the effects of cocaine. The lower DA levels produced by D,L-amphetamine are
supported by previous voltammetric data that indicated faster kinetics of DA
release and uptake in comparison to D-amphetamine and Adderall® (Chapters 3
and 4) (Fig. 5.9b) and also the approximate D-amphetamine in this drug solution
was only half of the other amphetamine isomers in attempt to make comparisons
with the data in Chapter 3. L-amphetamine caused similar DA levels to the other
stimulants and replicated previous voltammetric data that demonstrated no
differences in evoked DA amplitudes when compared to D-amphetamine
(Chapter 3) (Fig. 5.9b).
Changes in Metabolite Levels Following Reverse Microdialysis of
Adderall®, D-amphetamine, Methylphenidate, and Reverse Adderall
Figure 5.5 shows the individual tracings of detected DOPAC levels
(represented as % of baseline) following reverse microdialysis of D-amphetamine
at multiple concentrations. While some variability was found, D-amphetamine
generally caused a dose-dependent decrease in DOPAC levels similar to
Adderall and Reverse Adderall. The resulting response curve for changes in
DOPAC levels did not mimic the double-sigmoidal pattern seen in the response
curve of DA.

D-amphetamine, Adderall®, and Reverse Adderall decreased

DOPAC levels in a similar manner following local perfusion of drug at 120
minutes and continued to decrease DOPAC production up to one hour when
DOPAC levels returned to baseline (Fig. 5.5-5.8). While methylphenidate caused
increased DA levels similar to the other stimulants, it did not affect DOPAC levels
in a consistent manner and was similar in this aspect to the effects of cocaine.
Table 5.1 shows the concentrations that caused a half-maximal response
extrapolated from the response curves for DOPAC. Differences in the maximal
stimulant concentration effects on DOPAC levels are shown in Figures 5.10 a, b.
DOPAC production was less significantly affected by methylphenidate and
cocaine in comparison to Adderall® (p<0.001; Fig. 5.10a), and D-amphetamine
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(p<0.01, p<0.05; Fig. 5.10a).

Reverse Adderall, L-amphetamine, and D,L-

amphetamine all caused significantly greater effects on DOPAC levels in
comparison to cocaine (p<0.001; Fig. 5.10b). An initial increase in DOPAC was
seen following application of 100 µM and 400 µM methylphenidate followed by a
decrease similar to that of other concentrations without a dose-dependent pattern
(Fig. 5.6). Figure 5.11 shows measures of HVA following reverse microdialysis
of D-amphetamine, methylphenidate, Adderall®, and Reverse Adderall. No clear
dose-response pattern was detected across measures of HVA supported by the
decreased levels of HVA in the rat CNS compared to nonhuman primates
(Cooper et al. 1996).
Discussion
These data represent novel findings regarding the effects of Damphetamine across a range of concentrations and the activity of local
applications of methylphenidate compared to its analog, cocaine.

The

concentration-response curve for D-amphetamine displayed a double-sigmoidal
pattern that supported dual-functionality properties of the DAT and/or differential
mechanisms by which high and low concentrations of D-amphetamine affect DA
efflux and DAT trafficking.

These data support potent increased DA levels

caused by local application of methylphenidate in a dose-dependent pattern.
Replicating our data in Chapter 4, Adderall® resulted in the most efficacious
effects on increased DA levels; while the EC50 (DA) of methylphenidate
supported the greatest potency when compared to the other stimulant
concentration-response data.

Decreased DA levels caused by cocaine

compared to higher DA levels after local application of methylphenidate indicate
a dissociation between the local effects of methylphenidate and cocaine.
Measures of DOPAC support differential interactions with the process of MAO
degradation of DA between amphetamine stimulants and methylphenidate.
Cocaine and methylphenidate were similar in effects on DOPAC production at
the highest concentrations.
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The data shown here were consistent with the known DA releasing
properties of amphetamine, predominantly due to the DAT reversal of normal
reuptake into the presynaptic terminal (Giros et al. 1996).

Likewise,

amphetamine has been shown to impair DA reuptake, inhibit MAO activity, and
affect vesicular conditions that lead to emptying of vesicular stores via the
vesicular monoamine transporter 2 (VMAT2) (Horn et al. 1971; Sulzer et al.
1995; Dubocovich et al. 1985; Heikkila et al. 1975; Uretsky and Snodgrass 1977;
Green and El Hait 1978; Cadoni et al 1995). To our knowledge, this is the first in
vivo study making use of local applications of a range of concentrations in drug
naïve animals. We chose to carry out these studies in this manner based on
information supporting the dynamic changes that occur in DA neuronal systems
in response to DAT substrates and inhibitors. Purdom et al. (2003) showed data
supporting that the order of administration of different concentrations of Damphetamine significantly affected DA and DOPAC levels. These results were
attributed to persistent changes in DAT membrane availability and/or function.
Other in vitro studies have shown substrate dependent trafficking of the DAT to
and from the plasma membrane and subsequent ability to transport DA (Kahlig et
al. 2005; Johnson et al. 2005; Saunders et al. 2000; Kahligh et al. 2004; Kahlig
and Galli 2003).
One possible mechanism for the D-amphetamine double-sigmoidal
concentration-response curve involves targeting of specific DA pools and
amphetamine concentration-dependent effects. Some data support contribution
of both cytosolic and vesicular stores to the released DA following exposure to
amphetamine (Pifl et al. 1995); while other data indicate a predominant vesicular
DA contribution (Jones et al. 1998). Jones et al. (1998) measured DA released
following electrical stimulation and amphetamine perfusion of striatal brain slices
and noticed a delay in DA release with amphetamine, supporting that the DA had
to be redistributed to the cytosol prior to being released from the cell. Based on
these different contributions to amphetamine-evoked DA increases, our data are
in agreement with previous investigations that support lower concentrations of Damphetamine release “newly synthesized” DA pools in the cytosol, and higher
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concentrations contributed to the emptying of vesicular stores. As a result a
biphasic pattern and a marked increase in the amount of DA released at the
higher concentrations (Seiden et al. 1993; Langeloh and Trendelenburg 1987;
Sulzer et al. 1993, 2005).
An alternative mechanism for the D-amphetamine concentration-response
curve might be explained by an upregulation of DAT levels caused by stimulation
of D2R autoreceptors leading to second messenger regulation. Previous data
support a link between stimulation of D2R autoreceptors and levels of membrane
DATs (Parsons et al. 1993; Cass and Gerhardt 1994; Rothblat and Schneider
1997; Dickinson et al. 1999; Hoffman et al. 1999; Mayfield and Zahniser 2001).
For example, in vivo measures of DA have shown decreased DA clearance in the
striatum, prefrontal cortex, and nucleus accumbens after administration of the
D2R antagonist raclopride (Cass and Gerhardt 1994).

In addition, acute

amphetamine stimulation has been shown to cause increased synaptosomal
DAT surface expression that occurs within 30 seconds of treatment (Johnson et
al. 2005), while other reports have indicated rapid trafficking of the DAT. These
studies support that the effects we observed over 20 minutes could be caused by
DAT trafficking (Fleckenstein et al. 1999; Saunders et al. 2000). Due to the
comparatively increased sensitivity of D2R autoreceptors, low levels of
extracellular DA are sufficient to stimulate these autoreceptors that would result
in increased DA clearance (Cooper et al. 2003) (Fig. 5.12). The small amounts
of released DA required to stimulate these autoreceptors would be taken up
quickly through increased levels of membrane DATs, supporting the effects we
see with the first plateau of the D-amphetamine concentration-response curve.
At higher concentrations of D-amphetamine, increased DAT trafficking to the
membrane will likely occur; however, the higher concentrations of Damphetamine will more potently cause reverse transport of DATs to move DA
into the extracellular space (Khoshbouei et al. 2004; Gorentla and Vaughan
2005) (Fig. 5.12).

The unaffected DATs will not be able to counteract this

response. Even though DAT levels are increasing, the increased levels of
amphetamine will also potently block eventual clearance of DA from the
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extracellular space. It is possible that D2R autoreceptor desensitization is likely to
occur which would decrease upregulation of DATs to the plasma membrane (Kim
et al. 2001; Namkung and Sibley 2004; Ferguson et al. 1996; Tang et al. 1994).
Finally, data support that interactions of amphetamine and the DAT lead to DAT
internalization via phosphorylation of target residues in the C- and N- termini
(Khoshbouei et al. 2004; Kahlig et al. 2006; Fog et al. 2006), providing theoretical
support for the effects we see in the second plateau of the D-amphetamine
concentration-response curve.
While the double plateaus we note here are in regards to increasing
concentrations of D-amphetamine, other reports suggest biphasic effects of
catecholamine transporters over different parameters.

Johnson et al. (2005)

described the effects of amphetamine on DAT surface expression in rat
synaptosomes. They described initial amphetamine upregulation of DATs to the
plasma membrane leading to DA efflux followed by amphetamine induced
internalization of DATs after repeated doses of amphetamine. Jayanthi et al.
(2005) described mechanisms that contribute to a biphasic regulation of
endogenous serotonin transporters (SERTs) expressed in platelets.

Protein

kinase c (PKC) activation in platelets resulted in the initial reduction of functional
SERTs followed by enhanced endocytosis of SERTs. Finally, due to the high
percentage of D-amphetamine in Adderall®, it is surprising that two plateaus of
the D-ampheatmine concentration-response curve are not distinguishable in the
Adderall® concentration-response curve.

Taking into consideration data from

Chapter 3, the faster kinetics of the effects of L-amphetamine in combination with
the slower kinetics of D-amphetamine could either mask 1) the noticeable
differences of source (cytosolic versus vesicular) contribution of DA or 2) the
effects on DAT trafficking.
The increased DA levels we report after reverse microdialysis of
methylphenidate were in contrast to our hypothesis that local applications of
methylphenidate would not cause increased DA levels in an anesthetized rat.
Due to reports that methylphenidate mainly works to block reuptake of impulsereleased DA from predominantly vesicular stores (Sonders et al. 1997; Clemens
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et al. 1979; Volkow et al. 1998) and is thought to mainly be a DAT blocker
(Riddle et al. 2005; Bergman et al. 1989), it was surprising that enough
spontaneous release occurred in anesthetized rats to cause accumulation of DA.
These studies were carried out in anesthetized F344 rats and the urethane
anesthesia that we use here has been shown to markedly decrease intrinsic
neuronal firing rates but not affect DAT activity mediated by local applications of
stimulants (Warenycia and McKenzie 1988; Sabeti et al. 2003).

While

spontaneous firing rates measured by multiple single-unit electrophysiology were
significantly decreased after anesthesia in a freely-moving animal, they were not
completely ablated in the striatum (Kish et al. 1999).

Sonders et al. (1997)

classified methylphenidate in a group of pharmacological agents that are
cocaine-like in terms of voltage dependence of their subtractive currents from
control current and placed amphetamine in a category similar to measures in the
presence DA, the endogenous substrate for the DAT. Our results are consistent
with the effects of intraperitoneal administration of methylphenidate in freelymoving rat microdialysis studies (Berridge et al. 2006). Additionally, our data
parallel a study that investigated the neurochemical effects of subcutaneously
administered DA uptake inhibitors and releasers in anesthetized rats. Hurd and
Ungerstedt (1989) found that amphetamine and methylphenidate caused similar
increases in DA levels however methylphenidate caused these levels over a
longer time period. This study also reported that methylphenidate had less of an
effect on decreasing DOPAC levels compared to the more pronounced decrease
caused by amphetamine (Hurd and Ungerstedt 1989). Our data were similar to
others in the effects of methylphenidate in comparison to amphetamine on
behavior.

Similar to D-amphetamine, methylphenidate has been shown to

induce locomotor activity at low doses and cause stereotypies at higher doses
(Fessler et al. 1980; Hughes and Greig 1976; Scheel-Kruger 1971). Additionally,
methylphenidate has also been found to be reinforcing in regards to drug abuse
potential in humans, and it has been self-administered by animal models (Stoops
et al. 2005; Rush et al. 2001; Risner and Jones 1976). In general, cocaine and
methylphenidate are thought to work in a similar manner by predominantly acting
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as competitive inhibitors of the DAT and increases in extracellular DA result
predominantly from this blockade after impulse-dependent release of DA.
Other studies have brought forward some inconsistencies and support that
cocaine-like, DAT blockers may have DA releasing properties (Stamford et al.
1989; Shore 1976; Ewing et al. 1983; Venton et al. 2006). Additional evidence
support that these DAT inhibitors must act in a local manner due to studies that
have shown cocaine-evoked DA release in striatal terminals isolated from cell
bodies (Lee et al. 1996).

Finally, Russell et al. (1998) demonstrated that

methylphenidate caused DA release in brain slices mainly from vesicular stores
and suggested that vesicular function may be impaired in ADHD neuropathology,
and another study also showed methylphenidate induced DA increases with
microdialysis (Butcher et al. 1991).
These data support the differential local effects of methylphenidate and a
potential dissociation of the effects of cocaine and methylphenidate. Increased
DA levels caused by local applications of methylphenidate were not significantly
different from DA levels caused by cocaine. However, on average, DA levels
after cocaine were lower than DA levels after applications of methylphenidate,
and methylphenidate caused DA levels similar to the amphetamine isomers. It is
possible that methylphenidate has DA releasing properties other than just
blockade of the DAT.
While the argument can be made that these local applications failed to
account for pharmacokinetic differences between these stimulants, we propose
that this is a particular strength of our study. For these experiments, drugs were
applied

over

a

range

of

concentrations,

including

clinically

relevant

concentrations (10-50 µM) and potentially drug abuse levels (>400 µM) (West et
al. 1999; Shader et al. 1999; Kuczenski and Segal 2001; Solanto et al. 2001;
Grilly and Loveland 2001). The low concentrations were projected to simulate
potential levels of drug that would be present in brain tissue following systemic or
oral administration. Finally, administering the drugs via reverse microdialysis
eliminated pharmacokinetic issues from the study.
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In summary, we have shown that the D-amphetamine concentrationresponse curve of DA displayed a double plateau pattern indicating effects on DA
stores and/or rapid regulation of DAT trafficking and/or function.

This study

provides important information describing the effects of stimulants over clinically
relevant and possibly abuse levels on DA neurotransmission and metabolite
production. These data support that methylphenidate may cause DA release in
addition to acting as a DA uptake inhibitor. Taken together, these data explain
the effects of clinically available stimulants on DA levels over a range of
concentrations and how alternative combinations of amphetamine isomers show
promising effects.
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EC50 [Drug] (μM)

EC50 [Drug] (µM)

For DA

For DOPAC

D-amphetamine I

0.5

Not Determined

D-amphetamine II

50

5

Methylphenidate

10

1

Adderall®

25

10

Reverse Adderall

50

25

Drug

Table 5.1 Stimulant Potency on DA and DOPAC Measures
Values determined for EC50 represent extrapolation of potency measures from
the stimulant concentration response curves of DA and DOPAC.
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Figure 5.1 D-amphetamine Concentration-Response Curve for DA with a
Double Plateau
a. Complete D-amphetamine concentration-response curve of DA levels after
reverse microdialysis in the striatum of rat brain with two plateaus. b. Mean
individual microdialysis sample runs are shown including collection over two
hours for basal DA measures followed by a 20 minute local application of drug
(respective concentration) in the aCSF (arrow indicates time point of stimulation)
and completed with perfusion of aCSF for 100 minutes longer.

Inset:

Representation of each average peak response including aCSF (a) control (n=5
rats per concentration; error bars represent S.E.M.).
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Figure 5.2 Methylphenidate Concentration-Response Curve of DA
a. Complete methylphenidate concentration-response curve of DA levels after
reverse microdialysis in the striatum of rat brain. b. Mean microdialysis sample
runs are shown including collection over two hours for basal DA measures
followed by a 20 minute local application of drug (respective concentration) in the
aCSF (arrow indicates time point of stimulation) and completed with perfusion of
aCSF for 100 minutes longer.

Inset:

representation of each average peak

response including aCSF (a) control (n=5 rats per concentration; error bars
represent S.E.M.).
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Figure 5.3 Adderall® Concentration-Response Curve of DA
a. Complete Adderall® concentration-response curve of DA levels after reverse
microdialysis in the striatum of rat brain.

b.

Mean individual microdialysis

sample runs are shown including collection over two hours for basal DA
measures followed by a 20 minute local application of drug (respective
concentration) in the aCSF (arrow indicates time point of stimulation) and
completed with perfusion of aCSF for 100 minutes longer. Inset: representation
of each average peak response including aCSF (a) control (n=5 rats per
concentration; error bars represent S.E.M.).
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Figure 5.4 Reverse Adderall Concentration-Response Curve of DA
a. Complete Reverse Adderall concentration-response curve of DA levels after
reverse microdialysis in the striatum of rat brain.

b.

Mean individual

microdialysis sample runs are shown including collection over two hours for basal
DA measures followed by a 20 minute local application of drug (respective
concentration) in the aCSF (arrow indicates time point of stimulation) and
completed with perfusion of aCSF for 100 minutes longer. Inset: representation
of each average peak response including aCSF (a) control (n=5 rats per
concentration; error bars represent S.E.M.).
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Figure 5.5 D-amphetamine Response Curve for DOPAC (% of Baseline)
a.

Complete D-amphetamine response curve of DOPAC production after

reverse microdialysis in the striatum of rat brain.

b.

Mean individual

microdialysis sample runs are shown including collection over two hours for basal
DOPAC measures followed by a 20 minute local application of drug (respective
concentration) in the aCSF (arrow indicates time point of stimulation) and
completed with perfusion of aCSF for 100 minutes longer.

Inset:

Average

representation of each peak response including aCSF (a) control (n=5 rats per
concentration; data are represented in percent of baseline calculated from the
change occurring 20 minutes after stimulation at time point 140 minutes; error
bars represent S.E.M. for percent of baseline).
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Figure 5.6 Methylphenidate Response Curve of DOPAC (% of Baseline)
a. Complete methylphenidate response curve of DOPAC production after reverse
microdialysis in the striatum of rat brain.

b.

Mean individual microdialysis

sample runs are shown including collection over two hours for basal DOPAC
measures followed by a 20 minute local application of drug (respective
concentration) in the aCSF (arrow indicates time point of stimulation) and
completed with perfusion of aCSF for 100 minutes longer. Inset: representation
of each average peak response including aCSF (a) control

(n=5 rats per

concentration; data are represented in percent of baseline calculated from the
change occurring 20 minutes after stimulation at time point 140 minutes; error
bars represent S.E.M. for percent of baseline).
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Figure 5.7 Adderall® Response Curve of (DOPAC % Baseline)
a.

Complete Adderall® response curve of DOPAC production after reverse

microdialysis in the striatum of rat brain.

b.

Mean individual microdialysis

sample runs are shown including collection over two hours for basal DOPAC
measures followed by a 20 minute local application of drug (respective
concentration) in the aCSF (arrow indicates time point of stimulation) and
completed with perfusion of aCSF for 100 minutes longer. Inset: representation
of each average peak response including aCSF (a) control

(n=5 rats per

concentration; data are represented in percent of baseline calculated from the
change occurring 20 minutes after stimulation at time point 140 minutes; error
bars represent S.E.M. for percent of baseline).
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Figure 5.8 Reverse Adderall Response Curve of (DOPAC % of Baseline)
a.

Complete Reverse Adderall response curve of DOPAC production after

reverse microdialysis in the striatum of rat brain.

b.

Mean individual

microdialysis sample runs are shown including collection over two hours for basal
DOPAC measures followed by a 20 minute local application of drug (respective
concentration) in the aCSF (arrow indicates time point of stimulation) and
completed with perfusion of aCSF for 100 minutes longer. Inset: representation
of each average peak response including aCSF (a) control.

(n=5 rats per

concentration; data are represented in percent of baseline calculated from the
change occurring 20 minutes after stimulation at time point 140 minutes; error
bars represent S.E.M. for percent of baseline).
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Figure 5.9 Comparisons of Stimulant Efficacies on DA Levels
a. ADHD Drugs Versus Cocaine:

Comparisons of DA levels after reverse

microdialysis of the highest concentrations of ADHD medications tested in the
F344 rat striatum versus cocaine (all solutions are equimolar to D-amphetamine).
Adderall® (***p<0.001) and D-amphetamine (*p<0.05) caused significantly
greater DA levels than cocaine. There was a trend for methylphenidate to cause
greater DA levels than cocaine supporting a dissociation between the effects of
these two stimulants. b. Non-ADHD Drugs Versus Cocaine: Comparisons of
DA levels after reverse microdialysis of the highest concentrations of non-ADHD
amphetamine isomers tested in the F344 rat striatum versus cocaine. Reverse
Adderall (**p<0.01) and L-amphetamine (*p<0.05) caused significantly greater
DA levels than cocaine. (n=5 rats per concentration; data represent mean ±
S.E.M.).

98

Figure 5.10 Comparison of Stimulant Efficacies on DOPAC Levels (% of
Baseline)
a. ADHD Drugs Versus Cocaine:

DOPAC levels following reverse

microdialysis of the highest concentrations of ADHD stimulants tested in the
striatum of rat brain represented as percent of baseline (based on DOPAC
measures 20 minutes following stimulus). Adderall® (***p<0.001; ###p<0.001)
and D-amphetamine (**p<0.01; #p<0.05) had significantly greater effects on
DOPAC production in comparison to methylphenidate and cocaine respectively.
b. Non-ADHD Drugs Versus Cocaine:

DOPAC levels following reverse

microdialysis of the highest concentrations of non-ADHD stimulants tested in the
striatum of rat brain represented as percent of baseline (based on DOPAC
measures 20 minutes following stimulus). Reverse Adderall, L-amphetamine,
and D,L-amphetamine (***p<0.001) had significantly greater effects on DOPAC
production in comparison to cocaine (n=5 rats per concentration; data represent
mean ± S.E.M.).
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5.11 HVA Levels After Reverse Microdialysis of D-amphetamine,
Methylphenidate, Adderall®, and Reverse Adderall in the Striatum
HVA levels (% of Baseline) after local application of a. D-amphetamine, b.
methylphenidate, c. Adderall, and d. Reverse Adderall did not reveal a doseresponse pattern similar to DOPAC. Individual microdialysis sample runs are
shown including collection over two hours for basal DA measures followed by a
20 minute local application of drug (respective concentration) in the aCSF (arrow
indicates time point of stimulation) and completed with perfusion of aCSF for 100
minutes longer (n=5 rats for each concentration; data represent mean ± S.E.M.).
Refer to Fig. 5.1-5.8 for representation of concentrations and corresponding
colors.
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5.12 Theoretical Model of Activity Describing the Double Plateaus of the Damphetamine Concentration Response Curve for DA
Plateau I Low [D-amphetamine]:

Lower concentrations of D-amphetamine

cause reverse transport of low levels of DA through the DAT leading to
stimulation of DA sensitive D2R autoreceptors.

Autoreceptor stimulation has

been shown to signal the upregulation of functional DATs to the plasma
membrane to increase DA clearance (Parsons et al. 1993; Cass and Gerhardt
1994; Rothblat and Schneider 1997; Mayfield and Zahniser 2001). Due to the
increased clearance of DA, the first plateau of the concentration-response curve
potentially results. Plateau II High [D-amphetamine]: Amphetamine has been
shown to interact with DATs and facilitate DA release followed by DAT
internalization (Johnson et al. 2005; Fleckenstein et al. 1999; Saunders et al.
2000; Khoshbouei et al. 2004; Gorentla and Vaughan 2005).

Higher

concentrations of D-amphetamine will likely cause increased DA release and
DAT internalization.

D2R autoreceptor desensitization is likely to occur and

interrupt DAT expression (Kim et al. 2001; Namkung and Sibley 2004; Ferguson
et al. 1996; Tang et al. 1994). Higher levels of extracellular DA and decreased
DA clearance could cause the second plateau.
Copyright © Barry Matthew Joyce 2006
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Chapter 6: Discussion and Conclusions
Numerous

clinical

studies

have

provided

data

to

support

that

amphetamine isomer and stimulant dependent differences exist (James et al.
2005; Gross 1976; Arnold et al. 1972; 1976; Ahmann et al. 2001; Greenhill et al.
2001; Swanson et al. 1998; Biederman et al. 2006; Pelham et al. 1999; Bradley
1950; Smith and Davis 1977).

Additionally, animal studies have often been

inconclusive in describing amphetamine enantiomer differences (Stromberg and
Svensson 1975; Jones et al. 1974; Yokel and Pickens 1973; Kanbayashi et al.
2000; Hutchaleelaha et al. 1994; Risner and Jones 1975). Previous findings
from basic science studies have been limited by decreased sensitivity of the
techniques employed. The differences described in this dissertation are novel
and important findings generated via techniques with capabilities to measure low
levels of analyte in vivo.
Due to the known safety and efficacy of these medications, their clinical
use to treat ADHD has increased over the last few decades.

While the

stimulants we tested are known to be safe, there are unanswered questions that
merit further investigation. If we can determine the specific interactions of these
medications and their cellular targets then it will be possible to design analogue
drugs that have less abuse potential, increased efficacy, increased consistency
across patients, more accurate targeting of specific symptoms, and decreased
side effects. Finally, if different behavioral outcomes result following prescribed
use of stimulant medications, then correlations to specific patterns of
neurotransmission can allow for accurate determination of the necessary
components of stimulant treatments that may be forthcoming. Our studies have
sought to address some of these questions by completing the first studies, to our
knowledge, that look at these drugs and their components’ interactions with DA
neurotransmission.
In Chapter 3, we used microelectrodes and local applications of
amphetamine enantiomers to investigate differences in the effects on DA release
and regulation.

The majority of the in vivo investigations of amphetamine
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isomers have made use of only systemic amphetamine administration while
observing changes in measures of DA uptake or analyte level changes across
microdialysis samples.

Therefore, our first objective of these studies was to

determine if we could accurately and consistently evoke DA release signals at a
maximally effective concentration. After determining an effective concentration in
which we could consistently record DA release signals, we were able to test
multiple amphetamine isomers.

These recordings were completed in the

striatum, a region rich in DA nerve endings and an area implicated in human
anatomical studies of ADHD (Durston 2003; Solanto 2001; and Sowell et al.
2003). An important finding from these studies addressed previously reported
differences between D- and L- amphetamine; our data support that the two
enantiomers were similar in efficacy when applied locally to the striatum.
However, kinetic differences were found between D- and L-amphetamine that
support differential interactions and/or regulation of the DAT, the primary target of
amphetamine. When the two enantiomers were applied in combination, these
data indicate that resulting DA signal amplitudes were dependent on the amount
of D-amphetamine. Finally, kinetic differences were observed; D,L-amphetamine
caused transient DA release signals compared to the longer signals recorded
after local application of D-amphetamine. While these initial findings were some
of the first to show in vivo differences in amphetamine isomer effects on DA
release and uptake, we concluded that these concentrations were either in the
upper range or higher than clinically effective concentrations in the brain after
clinical use of amphetamine in humans (Shader et al. 1999; Solanto et al. 2001;
West et al. 1999; Grady et al. 1996; Seeman and Madras 2002).
In converse to studies completed for Chapter 3 in which we did not make
use of Adderall® to evoke DA release, we completed studies to investigate the
effects of clinically available Adderall® and D-amphetamine in Chapter 4. Based
on the data from Chapter 3, we maintained equimolar amounts of Damphetamine across all drug solutions and tested these at similar concentrations
to those in Chapter 3. To address concerns that the concentrations tested were
too high for clinical relevance, we also used lower drug concentrations. After
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determining that we could consistently measure the effects of decreased levels of
amphetamine isomers on DA release signal recordings; a complete analysis was
conducted of amphetamine isomers at these levels. An important finding from
these studies was that low-level Adderall® produced increased striatal DA
release and a prolonged time course compared to amphetamine isomers. While
the amplitude of DA release was significantly increased compared to D- and D,Lamphetamine, the kinetics of DA release signals were also significantly
elongated for Adderall®. These data support that the combination of salts and/or
enantiomers in Adderall contribute to a greater effect on the DAT in causing
reverse transport of DA over a longer period and a DAT blocking effect lasting
longer than the effects caused by amphetamine isomers. Since it is hard to
speculate what this increased effect on DA release and uptake caused by
Adderall® indicates without specific mechanistic investigations, the effect does
correlate with findings that Adderall® had longer lasting effects on symptoms of
locomotor activity compared to D-amphetamine in a recent clinical study (James
et al. 2001). We also replicated the significant difference in rise time between Damphetamine (slower) and D,L-amphetamine (faster) from Chapter 3 at these
low levels. While these concentrations of amphetamine isomers were lower in
magnitude, it is still difficult to verify the resulting effective concentration in the
brain and if these concentrations were maximally effective. Therefore reverse
microdialysis studies were necessary to identify and locally apply specific
effective concentrations that could be tested at much lower levels than were
studied in Chapters 3 and 4.
In Chapter 5 we used a different in vivo technique, intracerebral reverse
microdialysis, having decreased temporal and spatial resolution compared to the
electrochemical methods used in Chapters 3 and 4. This technique was chosen
to complete the concentration-response studies carried out in Chapter 5 because
of the ability to more accurately determine the effective concentrations in which
we wanted to locally apply in the striatum and the ability to sample the effects on
analytes of lower levels of amphetamine isomers due to the coupling of High
Performance Liquid Chromotography with electrochemical detection (HPLC-EC).

104

Finally, using microdialysis, we had the added ability to monitor the effects of
methylphenidate not possible with our current in vivo voltammetric techniques.
We

used

drug-naïve

animals

to

make

the

concentration-response

characterizations due to data that support changes in measures of DA levels
before and after exposure to amphetamine (Purdom et al. 2003).
One major finding in Chapter 5 was that the concentration-response curve
of D-amphetamine had two plateaus. These data are among the first to directly
support a dissociation in the effects of high and low doses of amphetamine on
the DAT. These data correlate with previous findings that 1) different sources of
cellular DA are affected by different stimulants or 2) biphasic regulation of the
DAT (Langeloh and Trendelenburg 1987; Sulzer et al. 2005,1993; Jones et al.
1998; Johnson et al. 2005;

Jayanthi et al. 2005; Kahlig et al. 2005).

The

concentration-response curve of D-amphetamine supports differences in the
effects of low versus high-level stimulants that could correlate with clinical versus
drug abuse levels. The biphasic properties of the D-amphetamine concentrationresponse curve are supported by other studies that have provided evidence in
biphasic regulation of catecholamine transporters and data that support the
release of different DA stores. Finally, this concentration-response curve could
be the first in vivo observation of the paradoxical effects of stimulants in humans.
Low doses are known to reduce locomotor activity and distractibility in humans,
while higher doses have caused sleeplessness and restlessness (Seeman and
Madras 2002).
A second major finding of the data in Chapter 5 is the robust increase in
DA levels caused by methylphenidate in the anesthetized rat. Methylphenidate is
generally regarded to contribute to impulse-dependent accumulation of DA
(Bergman et al. 1989). Based on the similar increases in DA levels caused by
methylphenidate and the other amphetamine analogs, methylphenidate either
blocked reuptake of impulse-released DA or displaced DA from DA neurons
when applied locally. Due to the decreased sensitivity of temporal measures with
this technique, we no longer saw distinct differences in the effects of these
stimulants, in particular at the suspected clinical levels. Finally, we compared
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these

stimulants

with

cocaine,

a

drug

that

has

been

grouped

with

methylphenidate and impulse-dependent accumulation of DA (Sonders et al.
1997). Our data support that methylphenidate increased DA levels more similar
to the effects of amphetamine than cocaine.

These data have important

implications regarding the potential dissociation of the properties of cocaine and
methylphenidate and promote a unified theory that initially increasing DA
neurotransmission is important for decreasing the symptoms of ADHD.
Combined, these in vivo data have replicated clinical and animal
behavioral observations that stimulants have different effects on behavioral
outcomes. Chapter 3 brought about the relationship of L-amphetamine’s effects
on D-amphetamine-evoked DA release, since the two were not additive in their
effects on DA signal amplitudes when applied together but demonstrated a
regulatory mechanism. In regards to these data, we proposed that differential
amphetamine enantiomer interactions with the DAT and resulting effects on DAT
function/expression occur. In Chapters 4 and 5 we propose more theoretical
explanations of the effects on the DAT and what these data represent. Not only
do these data reveal differences between enantiomers but also differences that
are present between varying ratios of D and L-amphetamine. While the effects of
D- and L- amphetamine were not additive in Chapter 3, the sum of their effects
may indicate why a 75% D- and 25% L-amphetamine mixture had the greatest
effects on DA in Chapter 4. According to the data in Chapter 3, L-amphetamine
caused faster DA release and therefore a relatively small amount of Lamphetamine in Adderall® could prime the DAT for a relatively greater proportion
of D-amphetamine to cause a more robust and elongated effect on DA
neurotransmission. In regards to our robust effects with Adderall in Chapter 4,
most of the literature support that stimulants that cause fast abrupt increases in
DA are more reinforcing or likely to be abused (Volkow 2006; Volkow and
Swanson 2003).

Conversely, drugs and delivery systems that cause slower

effects on DAT blockade and DA increases are thought to have less abuse
liability (Spencer et al. 2006). It is possible that Adderall displays a trend to fall
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into the latter category of medications due to our data that support the elongated
effects of Adderall.
Future Investigations of Stimulant Medications
In conclusion, we have made progress in conducting some of the first in
vivo experiments to date looking at stimulant drugs in the context of their clinical
and therapeutic use.

The differences that we report are novel because

techniques with the sensitivity to measure the effects of low-levels of drugs have
not been available previously, the studies were carried out in drug-naïve animals
to study the effects in brain tissue with decreased variability, and the drugs were
applied locally to eliminate drug pharmacokinetic issues from these studies.
Future studies are necessary to characterize the effects of amphetamine isomers
and methylphenidate on other neurotransmitters and brain regions such as the
prefrontal cortex.

In addition, animal models of ADHD are forthcoming and

locally applied stimulant effects should be studied in these models (Solanto et al.
2001; Giros et al. 1996; Wultz et al. 1990; Van Den Buuse and De Jong 1989;
Hess et al. 1992, 1996). The development of microelectrode arrays that have
capabilities to assess multiple neurotransmitters and target recordings in more
discrete brain loci by our lab will allow for investigations of the effects of
stimulants on glutamate, norepinephrine, and 5-HT neurotransmission in the
striatum, prefrontal cortex, and cerebellum (Nickell et al. 2005, 2006; Day et al.
2006; Pomerleau et al. 2003; Burmeister et al. 2002).

According to current

estimates, 120,000,000 prescriptions have been given since we began collecting
the data for this dissertation (Vendentam 2006). Knowing that these drugs are
safe and effective is no longer sufficient to neglect necessary studies to
characterize their properties that could yield more efficient, selective ADHD
medications with less side effects and abuse potential.
Copyright © Barry Matthew Joyce 2006
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Appendix 1: Comparisons of High Concentrations of D-amphetamine and
Adderall®- Evoked DA Release in the Rat Striatum
For these in vivo voltammetric studies, two different amphetamine
solutions were locally applied to evoke DA release signals in the striatum at
higher amounts than used in Chapter 4: D-amphetamine and Adderall® (mixed
from only amphetamine sulfate components of Adderall® to allow for the 75% Damphetamine: 25% L-amphetamine ratio) and D-amphetamine. The volume of
applied drug was kept constant at 500 nl and was measured using a dissection
microscope fitted with a calibrated reticule (1 mm change=25 nl of fluid) (Cass et
al. 1992, 1993a; Friedemann and Gerhardt 1992). Drugs were dissolved in 0.9%
physiological saline and final drug solutions were brought to a pH of 7.4. High
concentrations of D-amphetamine and Adderall were selected for use and were
applied in the following amounts 2 nanomoles D-amphetamine and 2.72
nanomoles Adderall®. Figure A1.1 shows a complete representative signal for
both drugs indicating no difference in amplitudes or signal decay, but a difference
in the time course of DA release.

When considering the amplitudes of DA

recordings in the striatum after application of Adderall® and D-amphetamine, the
mean amplitudes after local application of these drugs were not significantly
different (Fig. A1.2a). When comparing amplitude of DA release per nanoliter of
drug applied, there was no difference, indicating that either drug solution applied
at a similar volume is capable of producing a similar DA response signal (Fig
A1.2b). A comparison of rise times (TR) of the amphetamine-induced DA signals
in the striatum indicate significantly faster rise times in the presence of Damphetamine when compared to DA signals produced by Adderall® (p<0.01; Fig
A1.3a). When comparing the T80 signal decay times, indicative of DA uptake after
release, there was no significant difference between the average T80 decay time
of Adderall® and D-amphetamine (Fig A1.4b).
At the higher concentrations of Adderall® and D-amphetamine tested,
there were no differences in the amplitude of DA release signals which may be
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interpreted in two ways. The first description may reveal a caveat that these
concentrations result in a local tissue concentration that may be too high to
notice the differences, however this is unlikely when noticing the higher
amplitude generated in the presence of lower drug concentrations. The similar
amplitudes of the DA release signals caused by the higher concentrations of Damphetamine and Adderall® are smaller than the amplitudes of the DA release
signals evoked by the lower drug concentrations tested.

This supports a

potential inhibition of DAT reverse transport of DA at these levels of Damphetamine that likely has implications in situations of abuse or the paradoxical
effects that have classically been associated with stimulants (Stromberg and
Svensson 1975; Grilly and Loveland 2001). It is interesting that across the high
and low concentrations (from Chapter 4), the kinetics are similar. These data
strengthen the argument that studies with decreased stimulant concentrations
are

necessary

to

determine

potential

differences

in

effects

on

DA

neurotransmission as they relate to clinical use. While these data replicated the
major finding in Chapter 3, that the amount of DA release is dependent on the
amount of D-amphetamine applied; further investigations of these effects are
warranted in future studies.
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Figure A1.1 Representative DA Release Signals in the Striatum Caused by
Local Applications of Higher Levels of D-amphetamine and Adderall®
Typical recordings indicating the time course of DA release in the striatum of rat
brain induced by D-amphetamine (Triangles), and Adderall® (squares). All drug
solutions contain an equivalent 2 nmol of D-amphetamine. Inset: Measured
average in vivo redox ratios of all DA release signals, indicative of predominantly
DA, included for statistical analysis (n= 34, 49 signals; error bars represent
S.E.M.)
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Figure A1.2 Amplitudes of DA Release Signals in the Striatum After Local
Applications of Higher Levels of Adderall®, and D-amphetamine
a. The amplitudes of DA release measured in the rat striatum after local
application of Adderall® were not significantly different compared to Damphetamine. b. Amplitudes of DA (nM) recorded per volumes of drug applied
(nl) in the rat striatum were not different between Adderall® and D-amphetamine.
All drug solutions contained an equivalent 2 nmol of D-amphetamine.

Data

analyzed by MANOVA with Tukeys post-hoc comparisons; error bars represent
S.E.M. (n=animals, signals; 11, 49; 15, 34).
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Figure A1.3 Kinetics of DA Release Signals After Local Applications of
Higher Levels of Adderall® and D-amphetamine in the Striatum
a. Rise times for Adderall® evoked DA release signals in the rat striatum were
significantly longer than D-amphetamine evoked DA signals (**p<0.01). b. T80
decay times for Adderall® evoked DA release signals in the rat striatum were not
significantly longer than those produced by D-amphetamine. All drug solutions
contained an equivalent 2 nmol D-amphetamine. Data analyzed by MANOVA
with Tukeys post-hoc comparisons; error bars represent S.E.M. (n= animals,
signals; 11, 49; 15, 34).
Copyright © Barry Matthew Joyce 2006
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